https://ab-science.excalibra.com/veterinary-medicine-inflammatory-diseases/ 2010-01-01T15:37:44+00:00 https://ab-science.excalibra.com/veterinary-medicine-oncology/ 2011-09-22T15:37:21+00:00 https://ab-science.excalibra.com/human-medicine-central-nervous-system-diseases/ 2014-04-26T15:36:10+00:00 https://ab-science.excalibra.com/basic-research/ 2014-07-25T15:30:46+00:00 https://ab-science.excalibra.com/mast-cells-as-a-target/ 2015-01-21T15:30:46+00:00 https://ab-science.excalibra.com/human-medicine-oncology/ 2016-07-01T15:35:05+00:00 https://ab-science.excalibra.com/human-medicine-inflammatory-diseases/ 2017-06-22T15:35:05+00:00 https://ab-science.excalibra.com/defeating-the-dakota-access-pipeline-at-standing-rock/ 2018-04-18T14:52:33+00:00 https://ab-science.excalibra.com/wp-content/uploads/2018/04/image-35.jpg https://ab-science.excalibra.com/career-advancement-launches-new-grant-program-in-memory-of-pat-rosenzweig/ 2018-04-18T14:52:33+00:00 https://ab-science.excalibra.com/wp-content/uploads/2018/04/image-8.jpg https://ab-science.excalibra.com/a-modern-view-of-liberalism/ 2018-04-18T14:52:33+00:00 https://ab-science.excalibra.com/wp-content/uploads/2018/04/image-17.jpg https://ab-science.excalibra.com/frequently-asked-questions/ 2018-05-01T10:10:38+00:00 https://ab-science.excalibra.com/information-financiere/ 2018-05-02T10:09:45+00:00 https://ab-science.excalibra.com/wp-content/uploads/2018/05/logo_sf_01.jpg https://ab-science.excalibra.com/gouvernance/ 2018-05-02T10:09:59+00:00 https://ab-science.excalibra.com/foire-aux-questions/ 2018-05-02T10:10:38+00:00 https://ab-science.excalibra.com/documents-relatifs-aux-assemblees-generales/ 2018-05-02T10:12:34+00:00 https://ab-science.excalibra.com/document-de-reference/ 2018-05-02T10:12:34+00:00 https://ab-science.excalibra.com/autres-informations/ 2018-05-02T10:12:34+00:00 https://ab-science.excalibra.com/calendrier-financier/ 2018-05-02T10:12:34+00:00 https://ab-science.excalibra.com/rapports-financiers-annuels/ 2018-05-02T10:12:34+00:00 https://ab-science.excalibra.com/honoraires-des-commissaires-aux-comptes/ 2018-05-02T10:12:34+00:00 https://ab-science.excalibra.com/declaration-mensuelle-du-nombre-total-d-actions-en-circulation-et-des-droits-de-vote/ 2018-05-02T10:12:34+00:00 https://ab-science.excalibra.com/ab8939/ 2018-05-03T07:58:52+00:00 https://ab-science.excalibra.com/masitinib-in-inflammatory-diseases-2/ 2018-05-03T07:58:52+00:00 https://ab-science.excalibra.com/wp-content/uploads/2018/05/image04.jpg https://ab-science.excalibra.com/masitinib-in-oncology-2/ 2018-05-03T07:58:52+00:00 https://ab-science.excalibra.com/wp-content/uploads/2018/05/image06.jpg https://ab-science.excalibra.com/overview/ 2018-05-03T09:19:44+00:00 https://ab-science.excalibra.com/masitinib-in-neurology/ 2018-05-04T07:57:52+00:00 https://ab-science.excalibra.com/wp-content/uploads/2018/05/image01.jpg https://ab-science.excalibra.com/masitinib-general-overview/ 2018-05-05T07:52:34+00:00 https://ab-science.excalibra.com/wp-content/uploads/2018/05/image08.jpg https://ab-science.excalibra.com/message-from-the-ceo/ 2018-05-05T09:17:42+00:00 https://ab-science.excalibra.com/wp-content/uploads/2018/05/alain_moussy_president.jpg https://ab-science.excalibra.com/veterinary-medicine/ 2018-05-05T09:17:42+00:00 https://ab-science.excalibra.com/other-information/ 2018-05-05T10:12:34+00:00 https://ab-science.excalibra.com/general-meeting-preparatory-documents/ 2018-05-06T10:12:34+00:00 https://ab-science.excalibra.com/governance/ 2018-05-09T10:09:59+00:00 https://ab-science.excalibra.com/resume-de-la-webconference-tenue-le-8-juillet-2019/ 2019-07-09T05:00:00+00:00 https://ab-science.excalibra.com/autorisation-de-demarrer-letude-confirmatoire-de-phase-3-du-masitinib-dans-la-mastocytose-systemique-indolente/ 2019-10-24T04:00:00+00:00 https://ab-science.excalibra.com/leader-in-protein-kinase-inhibitor-development-for-amyotrophic-lateral-sclerosis-als/ 2020-09-11T14:11:55+00:00 https://ab-science.excalibra.com/about-ab-science/ 2020-09-11T14:11:55+00:00 https://ab-science.excalibra.com/results-of-the-combined-general-shareholders-meeting-of-august-31-2020/ 2020-11-06T07:24:54+00:00 https://ab-science.excalibra.com/ab-science-announces-the-publication-of-a-previously-unknown-mechanism-linked-to-the-progression-of-amyotrophic-lateral-sclerosis/ 2020-11-06T10:14:36+00:00 https://ab-science.excalibra.com/first-half-of-2018-revenues/ 2020-11-06T10:15:52+00:00 https://ab-science.excalibra.com/ab-science-reports-positive-idmc-recommendation-to-continue-the-study-based-on-a-trend-analysis-of-the-masitinib-phase-2-3-study-in-refractory-metastatic-colorectal-cancer/ 2020-11-06T10:17:54+00:00 https://ab-science.excalibra.com/results-of-the-combined-general-shareholders-meeting-held-on-june-29-2018/ 2020-11-06T10:19:05+00:00 https://ab-science.excalibra.com/combined-general-shareholders-meeting-held-on-june-29-2018/ 2020-11-06T10:20:59+00:00 https://ab-science.excalibra.com/ab-science-reports-positive-idmc-recommendation-based-on-an-interim-analysis-of-the-masitinib-phase-3-study-in-first-line-treatment-of-castrate-resistant-prostate-cancer/ 2020-11-06T10:22:31+00:00 https://ab-science.excalibra.com/ab-science-provides-update-on-eu-marketing-authorization-application-for-masitinib-in-the-treatment-of-amyotrophic-lateral-sclerosis/ 2020-11-06T10:23:45+00:00 https://ab-science.excalibra.com/annual-financial-results-as-of-december-31-2017/ 2020-11-06T10:24:38+00:00 https://ab-science.excalibra.com/ab-science-announces-that-the-chmp-has-adopted-a-negative-opinion-for-the-marketing-authorization-of-masitinib-in-amyotrophic-lateral-sclerosis/ 2020-11-06T10:25:47+00:00 https://ab-science.excalibra.com/corporate-presentation/ 2020-11-06T10:27:07+00:00 https://ab-science.excalibra.com/ab-science-announces-that-based-on-interim-analysis-idmc-recommended-the-continuation-of-the-masitinib-phase-3-study-in-progressive-forms-of-multiple-sclerosis-with-no-requirement-to-increase-the-stud/ 2020-11-06T10:34:27+00:00 https://ab-science.excalibra.com/etude-confirmatoire-positive-de-phase-3-ab12005-avec-le-masitinib-dans-le-cancer-du-pancreas-de-premiere-ligne-avec-douleur/ 2020-12-04T07:27:57+00:00 https://ab-science.excalibra.com/webcast-en-direct-le-jeudi-17-decembre-2020-sur-les-resultats-du-masitinib-dans-la-maladie-dalzheimer/ 2020-12-16T16:55:08+00:00 https://ab-science.excalibra.com/results-from-phase-2b-3-study-evaluating-masitinib-in-alzheimers-disease/ 2020-12-18T07:43:01+00:00 https://ab-science.excalibra.com/masitinib-in-alzheimers-disease-webcast-presentation/ 2020-12-21T21:39:15+00:00 https://ab-science.excalibra.com/boursorama-interview-of-alain-moussy-ceo-of-ab-science/ 2021-01-05T12:57:29+00:00 https://ab-science.excalibra.com/wp-content/uploads/2020/12/23-12-2020_Boursorama.jpg https://ab-science.excalibra.com/fr/interview-dans-boursorama-dalain-moussy-fondateur-dab-science/ 2021-01-06T16:35:32+00:00 https://ab-science.excalibra.com/wp-content/uploads/2020/12/23-12-2020_Boursorama.jpg https://ab-science.excalibra.com/capital-raise-for-a-total-amount-of-15-million-euros/ 2021-01-06T16:45:15+00:00 https://ab-science.excalibra.com/results-of-the-extraordinary-general-shareholders-meeting-of-december-16-2020/ 2021-01-06T16:45:49+00:00 https://ab-science.excalibra.com/corrective-press-release-regarding-adverse-events-information-from-study-ab09004/ 2021-01-06T16:46:22+00:00 https://ab-science.excalibra.com/fr/presentation-du-masitinib-dans-la-maladie-dalzheimer/ 2021-01-06T16:57:07+00:00 https://ab-science.excalibra.com/fr/resultats-de-lassemblee-generale-extraordinaire-des-actionnaires-du-16-decembre-2020/ 2021-01-06T16:57:55+00:00 https://ab-science.excalibra.com/fr/de-nouvelles-donnees-selectionnees-pour-une-presentation-orale-a-la-conference-2019-de-la-muscular-dystrophy-association/ 2021-01-20T09:17:38+00:00 https://ab-science.excalibra.com/fr/presentation-de-nouvelles-donnees-precliniques-sur-le-masitinib-dans-la-sla-lors-de-la-conference-2019-de-la-muscular-dystrophy-association/ 2021-01-20T09:23:10+00:00 https://ab-science.excalibra.com/resultats-financiers-annuels-au-31-decembre-2018-2/ 2021-01-20T09:25:31+00:00 https://ab-science.excalibra.com/fr/resultats-financiers-annuels-au-31-decembre-2018/ 2021-01-20T09:27:33+00:00 https://ab-science.excalibra.com/fr/levee-de-la-decision-de-suspension-des-etudes-cliniques-par-lansm/ 2021-01-20T09:37:32+00:00 https://ab-science.excalibra.com/fr/conference-web-les-4-et-5-juin-2019/ 2021-01-20T09:40:13+00:00 https://ab-science.excalibra.com/fr/presentation-de-la-conference-web-du-4-juin-2019/ 2021-01-20T09:45:54+00:00 https://ab-science.excalibra.com/fr/resume-de-la-webconference-tenue-le-4-juin-2019/ 2021-01-20T09:47:47+00:00 https://ab-science.excalibra.com/fr/presentation-de-la-conference-web-du-5-juin-2019/ 2021-01-20T09:49:56+00:00 https://ab-science.excalibra.com/fr/resume-de-la-webconference-tenue-le-5-juin-2019/ 2021-01-20T09:52:12+00:00 https://ab-science.excalibra.com/fr/lidmc-recommande-la-poursuite-de-letude-confirmatoire-du-masitinib-dans-le-cancer-du-pancreas-avec-douleur/ 2021-01-20T09:56:52+00:00 https://ab-science.excalibra.com/fr/resultats-de-lanalyse-intermediaire-pour-le-masitinib-dans-la-maladie-dalzheimer/ 2021-01-20T10:03:31+00:00 https://ab-science.excalibra.com/fr/validation-du-plan-de-developpement-clinique-de-la-molecule-ab8939-suite-a-la-procedure-reglementaire-de-scientific-advice/ 2021-01-20T10:10:03+00:00 https://ab-science.excalibra.com/fr/publication-de-letude-positive-de-phase-2-3-du-masitinib-dans-la-sla-dans-la-revue-amyotrophic-lateral-sclerosis-and-frontotemporal-degeneration/ 2021-01-20T10:17:23+00:00 https://ab-science.excalibra.com/fr/presentation-de-la-conference-web-du-8-juillet-2019/ 2021-01-20T10:22:30+00:00 https://ab-science.excalibra.com/fr/resume-de-la-webconference-tenue-le-8-juillet-2019/ 2021-01-20T10:22:50+00:00 https://ab-science.excalibra.com/resultats-de-letude-sur-le-masitinib-dans-le-melanome-metastatique-2/ 2021-01-20T10:24:09+00:00 https://ab-science.excalibra.com/fr/resultats-de-letude-sur-le-masitinib-dans-le-melanome-metastatique/ 2021-01-20T10:24:57+00:00 https://ab-science.excalibra.com/fr/point-sur-le-programme-clinique-sur-le-masitinib/ 2021-01-20T10:27:30+00:00 https://ab-science.excalibra.com/fr/ab-science-fera-une-presentation-lors-de-deux-prochaines-conferences-en-septembre-2019/ 2021-01-20T10:30:56+00:00 https://ab-science.excalibra.com/fr/10-millions-deuros-recoltes-grace-a-un-placement-prive/ 2021-01-20T10:33:20+00:00 https://ab-science.excalibra.com/fr/resultats-du-premier-semestre-2019/ 2021-01-20T10:43:58+00:00 https://ab-science.excalibra.com/fr/point-sur-le-calendrier-des-resultats-cliniques-du-masitinib/ 2021-01-20T10:45:58+00:00 https://ab-science.excalibra.com/fr/resultats-de-lassemblee-generale-mixte-du-28-juin-2019/ 2021-01-20T10:47:07+00:00 https://ab-science.excalibra.com/fr/autorisation-de-demarrer-letude-confirmatoire-de-phase-3-du-masitinib-dans-la-mastocytose-systemique-indolente/ 2021-01-20T10:49:49+00:00 https://ab-science.excalibra.com/fr/web-conference-sur-le-masitinib-dans-la-mastocytose-systemique-indolente-le-20-novembre-2019/ 2021-01-20T10:56:25+00:00 https://ab-science.excalibra.com/fr/accord-de-financement-visant-a-mobiliser-le-credit-impot-recherche-2019-de-maniere-anticipee/ 2021-01-20T10:59:13+00:00 https://ab-science.excalibra.com/fr/premiere-presentation-de-resultats-precliniques-de-la-molecule-ab8939-au-61eme-congres-annuel-de-lash/ 2021-01-20T11:02:01+00:00 https://ab-science.excalibra.com/fr/la-molecule-ab8939-obtient-la-designation-de-medicament-orphelin-aupres-de-la-fda-dans-le-traitement-de-la-leucemie-myeloide-aigue/ 2021-01-20T11:04:47+00:00 https://ab-science.excalibra.com/positive-top-line-phase-3-results-for-masitinib-in-severe-asthma/ 2021-01-20T11:08:45+00:00 https://ab-science.excalibra.com/fr/resultats-de-phase-3-positifs-du-masitinib-dans-lasthme-severe/ 2021-01-20T11:09:06+00:00 https://ab-science.excalibra.com/resume-du-webcast-avec-les-principaux-leaders-dopinion-sur-la-mastocytose-systemique-indolente-2/ 2021-01-20T11:10:18+00:00 https://ab-science.excalibra.com/fr/webcast-sur-le-masitinib-dans-lasthme-severe-le-lundi-2-decembre-2019/ 2021-01-20T11:23:18+00:00 https://ab-science.excalibra.com/fr/publication-de-nouveaux-resultats-dans-la-revue-glia-renforcant-la-plausibilite-du-mode-daction-du-masitinib-dans-la-sclerose-laterale-amyotrophique/ 2021-01-20T11:29:14+00:00 https://ab-science.excalibra.com/fr/la-fda-autorise-le-recrutement-de-patients-aux-usa-dans-letude-de-phase-3-du-masitinib-dans-le-traitement-du-cancer-de-la-prostate-hormono-resistant-eligible-a-la-chimiotherapie/ 2021-01-20T11:40:29+00:00 https://ab-science.excalibra.com/fr/resultats-de-phase-2b-3-positifs-du-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques/ 2021-01-20T11:42:52+00:00 https://ab-science.excalibra.com/fr/nouvelle-levee-de-fonds-de-123-millions-deuros/ 2021-01-20T11:45:30+00:00 https://ab-science.excalibra.com/resume-de-la-conference-web-avec-les-principaux-leaders-dopinion-autour-des-resultats-de-la-phase-2b-3-du-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques-2/ 2021-01-20T11:47:25+00:00 https://ab-science.excalibra.com/fr/publication-de-trois-resumes-detude-de-la-molecule-ab8939-dans-ledition-speciale-de-la-revue-blood-consacre-au-congres-annuel-de-lamerican-society-of-hematology-ash/ 2021-01-20T11:48:34+00:00 https://ab-science.excalibra.com/fr/resume-de-la-conference-web-avec-les-principaux-leaders-dopinion-autour-des-resultats-de-la-phase-2b-3-du-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques/ 2021-01-20T11:49:16+00:00 https://ab-science.excalibra.com/fr/lettre-a-nos-partenaires-concernant-limpact-de-la-pandemie-covid-19-sur-les-etudes-cliniques-dab-science/ 2021-01-20T11:56:02+00:00 https://ab-science.excalibra.com/fr/resultats-financiers-annuels-au-31-decembre-2019/ 2021-01-20T11:57:56+00:00 https://ab-science.excalibra.com/fr/autorisation-de-lagence-francaise-du-medicament-ansm-dinitier-une-etude-de-phase-2-evaluant-le-masitinib-en-combinaison-avec-lisoquercetine-dans-le-traitement-du-covid-19/ 2021-01-20T12:01:28+00:00 https://ab-science.excalibra.com/fr/presentation-des-resultats-de-letude-de-phase-3-dab-science-ab7015-du-masitinib-dans-lasthme-severe-au-congres-annuel-2020-de-leuropean-academy-of-allergy-cli/ 2021-01-20T12:07:01+00:00 https://ab-science.excalibra.com/fr/conference-web-le-lundi-11-mai-2020-sur-le-masitinib-en-combinaison-avec-lisoquercetine-dans-le-traitement-du-covid-19/ 2021-01-20T12:11:34+00:00 https://ab-science.excalibra.com/fr/report-de-lassemblee-generale-annuelle-des-actionnaires-dab-science/ 2021-01-20T12:15:16+00:00 https://ab-science.excalibra.com/presentation-of-the-results-from-ab8939-preclinical-program-in-aml-in-eha-2020-annual-congress/ 2021-01-20T12:18:01+00:00 https://ab-science.excalibra.com/fr/presentation-des-resultats-precliniques-de-la-molecule-ab8939-au-congres-annuel-de-lassociation-europeenne-dhematologie-aeh/ 2021-01-20T12:18:19+00:00 https://ab-science.excalibra.com/new-results-published-in-journal-of-alzheimer-s-disease-support-masitinib-s-potential-mode-of-action-in-alzheimer-s-disease/ 2021-01-20T12:23:34+00:00 https://ab-science.excalibra.com/fr/de-nouveaux-resultats-publies-dans-la-revue-medicale-evaluee-par-des-pairs-journal-of-alzheimers-disease-renforcent-la-plausibilite-du-mode-daction-du-masitinib-dans-la-maladie-d/ 2021-01-20T12:23:51+00:00 https://ab-science.excalibra.com/fr/resultats-de-lassemblee-generale-mixte-du-31-aout-2020/ 2021-01-20T12:25:25+00:00 https://ab-science.excalibra.com/ab-science-to-present-results-from-its-ab07002-study-in-progressive-forms-of-ms-at-msvirtual2020/ 2021-01-20T12:31:00+00:00 https://ab-science.excalibra.com/fr/ab-science-presentera-les-resultats-de-son-etude-de-phase-2b-3-ab07002-dans-les-formes-progressives-de-la-sclerose-en-plaques-a-la-msvirtual2020/ 2021-01-20T12:31:48+00:00 https://ab-science.excalibra.com/ab-science-to-present-results-from-its-ab07015-study-in-severe-asthma-at-the-annual-european-respiratory-society-international-congress/ 2021-01-20T12:35:31+00:00 https://ab-science.excalibra.com/fr/ab-science-presentera-les-resultats-de-son-etude-de-phase-3-dans-lasthme-severe-au-congres-annuel-international-de-european-respiratory-society/ 2021-01-20T12:36:26+00:00 https://ab-science.excalibra.com/ab-science-presents-phase-2b-3-study-results-in-progressive-multiple-sclerosis-at-the-worlds-largest-multiple-sclerosis-research-conference/ 2021-01-20T12:37:50+00:00 https://ab-science.excalibra.com/fr/ab-science-devoile-les-resultats-de-son-etude-de-phase-iib-iii-dans-les-formes-progressives-de-la-sclerose-en-plaques-a-loccasion-du-plus-grand-congres-international-sur-la-sclerose-en-plaque/ 2021-01-20T12:38:30+00:00 https://ab-science.excalibra.com/first-half-of-2020-results/ 2021-01-20T12:39:43+00:00 https://ab-science.excalibra.com/results-from-masitinib-study-ab07015-in-severe-asthma-selected-for-presentation-at-an-american-thoracic-society-symposium/ 2021-01-20T12:42:43+00:00 https://ab-science.excalibra.com/fr/resultats-de-letude-ab07015-du-masitinib-dans-lasthme-severe-seront-presentes-au-colloque-de-lamerican-thoracic-society-ats-du-16-octobre-2020/ 2021-01-20T12:43:07+00:00 https://ab-science.excalibra.com/positive-top-line-phase-3-results-for-oral-masitinib-in-severe-asthma/ 2021-01-20T12:45:29+00:00 https://ab-science.excalibra.com/fr/resultats-positifs-de-phase-3-du-masitinib-dans-lasthme-severe/ 2021-01-20T12:46:22+00:00 https://ab-science.excalibra.com/financing-of-4-5-million-euros-through-the-issuance-of-bonds-convertible-into-new-ordinary-shares/ 2021-01-20T12:52:34+00:00 https://ab-science.excalibra.com/fr/financement-de-45-millions-deuros-par-emission-dobligations-convertibles-en-actions-ordinaires-nouvelle/ 2021-01-20T12:53:02+00:00 https://ab-science.excalibra.com/fr/signature-dun-accord-de-financement-de-150-millions-deuros-avec-la-banque-europeenne-dinvestissement/ 2021-01-20T13:02:23+00:00 https://ab-science.excalibra.com/fr/etude-confirmatoire-positive-de-phase-3-ab12005-avec-le-masitinib-dans-le-cancer-du-pancreas-de-premiere-ligne-avec-douleur/ 2021-01-20T13:04:57+00:00 https://ab-science.excalibra.com/fr/communique-de-presse-rectificatif-concernant-les-informations-sur-les-evenements-indesirables-de-letude-ab09004/ 2021-01-20T13:10:45+00:00 https://ab-science.excalibra.com/fr/resultats-de-letude-de-phase-2b-3-evaluant-le-masitinib-dans-la-maladie-dalzheimer/ 2021-01-20T13:12:31+00:00 https://ab-science.excalibra.com/fr/levee-de-fonds-pour-un-montant-total-de-15-millions-deuros/ 2021-01-20T13:13:37+00:00 https://ab-science.excalibra.com/fr/mise-au-point-dab-science-concernant-larticle-publie-hier-dans-le-journal-les-echos-concernant-lenquete-en-cours-de-lautorite-des-marches-financiers/ 2021-01-20T13:30:59+00:00 https://ab-science.excalibra.com/fr/resume-du-webcast-sur-la-mastocytose-systemique-indolente/ 2021-01-20T13:37:06+00:00 https://ab-science.excalibra.com/fr/de-nouvelles-recherches-independantes-revelent-que-le-masitinib-a-une-activite-anti-virale-in-vitro-directe-contre-le-virus-sars-cov-2/ 2021-01-20T13:49:46+00:00 https://ab-science.excalibra.com/new-independent-research-reveals-that-masitinib-has-direct-anti-viral-activity-against-the-sars-cov-2-virus-in-vitro/ 2021-01-20T13:51:35+00:00 https://ab-science.excalibra.com/postponement-of-ab-science-annual-general-shareholders-meeting/ 2021-01-20T13:52:57+00:00 https://ab-science.excalibra.com/fr/etude-confirmatoire-ab09004-positive-de-phase-2-3-avec-le-masitinib-dans-la-maladie-dalzheimer/ 2021-01-20T15:18:26+00:00 https://ab-science.excalibra.com/fr/webcast-en-direct-le-jeudi-17-decembre-2020-sur-les-resultats-du-masitinib-dans-la-maladie-dalzheimer/ 2021-01-20T15:20:53+00:00 https://ab-science.excalibra.com/fr/pacttm-dans-la-limite-de-4-millions-dactions-avec-un-fonds-controle-par-alpha-blue-ocean/ 2021-01-20T15:22:12+00:00 https://ab-science.excalibra.com/fr/resultats-du-premier-semestre-2020/ 2021-01-21T09:59:18+00:00 https://ab-science.excalibra.com/fr/le-masitinib-a-une-activite-anti-virale-contre-le-virus-du-sras-cov-2-in-vitro/ 2021-01-25T08:37:16+00:00 https://ab-science.excalibra.com/a-new-independent-publication-confirms-that-masitinib-has-anti-vital-activity-against-the-sars-cov-2-virus-in-vitro/ 2021-01-25T08:41:17+00:00 https://ab-science.excalibra.com/fr/nouvelle-publication-independante-confirmant-le-role-du-masitinib-comme-therapie-potentielle-dans-le-cancer-du-pancreas/ 2021-02-23T07:38:48+00:00 https://ab-science.excalibra.com/a-new-independent-publication-confirms-the-role-of-masitinib-as-a-potential-therapy-in-pancreatic-cancer/ 2021-02-23T07:42:00+00:00 https://ab-science.excalibra.com/fr/nouvelle-publication-independante-confirmant-le-role-du-masitinib-comme-therapie-potentielle-dans-les-troubles-neurodegeneratifs/ 2021-03-08T07:59:50+00:00 https://ab-science.excalibra.com/a-new-independent-publication-confirms-the-role-of-masitinib-as-a-potential-therapy-in-neurodegenerative-disorders/ 2021-03-08T08:01:03+00:00 https://ab-science.excalibra.com/fr/mise-a-jour-concernant-l-etude-de-phase-3-du-masitinib-dans-le-cancer-de-la-prostate/ 2021-03-31T16:13:43+00:00 https://ab-science.excalibra.com/update-on-masitinib-phase-3-study-in-prostate-cancer/ 2021-03-31T16:15:28+00:00 https://ab-science.excalibra.com/fr/signature-accord-licence-exclusif-avec-universite-de-chicago-covid-19/ 2021-04-06T06:20:46+00:00 https://ab-science.excalibra.com/signing-of-an-exclusive-licensing-agreement-with-the-university-of-chicago-to-conduct-research-for-the-prevention-and-treatment-of-covid-19/ 2021-04-06T06:22:31+00:00 https://ab-science.excalibra.com/ab-science-secures-6me-in-non-dilutive-financing-guaranteed-by-the-french-government/ 2021-04-14T16:26:13+00:00 https://ab-science.excalibra.com/fr/ab-science-obtient-un-financement-non-dilutif-de-6me-garanti-par-letat-francais/ 2021-04-14T16:30:20+00:00 https://ab-science.excalibra.com/masitinib-phase-2b-3-study-in-prostate-cancer-met-its-primary-endpoint/ 2021-04-29T17:19:35+00:00 https://ab-science.excalibra.com/fr/l-etude-de-phase-2b-3-du-masitinib-dans-le-cancer-de-la-prostate-a-atteint-son-critere-devaluation-principal/ 2021-04-30T16:57:00+00:00 https://ab-science.excalibra.com/annual-financial-results-as-of-31-december-2020/ 2021-04-30T17:03:47+00:00 https://ab-science.excalibra.com/fr/resultats-financiers-annuels-au-31-decembre-2020/ 2021-04-30T17:05:56+00:00 https://ab-science.excalibra.com/fr/selection-pour-presentation-a-la-reunion-annuelle-de-lasco-des-resultats-de-letude-ab12005-du-masitinib-dans-le-cancer-du-pancreas/ 2021-05-20T16:19:41+00:00 https://ab-science.excalibra.com/fr/conference-virtuelle-sur-les-resultats-du-masitinib-dans-le-cancer-de-la-prostate-le-mardi-25-mai-2021/ 2021-05-21T16:12:03+00:00 https://ab-science.excalibra.com/live-webcast-on-tuesday-may-25-2021-on-masitinibs-results-in-prostate-cancer/ 2021-05-21T20:34:00+00:00 https://ab-science.excalibra.com/fr/presentation-de-la-conference-virtuelle-du-25-mai-2021-sur-le-masitinib-dans-le-cancer-de-la-prostate/ 2021-05-25T17:58:07+00:00 https://ab-science.excalibra.com/presentation-of-the-webcast-held-on-may-25-2021-on-masitinib-in-prostate-cancer/ 2021-05-25T18:00:13+00:00 https://ab-science.excalibra.com/fr/resultats-de-l-etude-de-phase-3-evaluant-le-masitinib-dans-le-cancer-de-la-prostate/ 2021-05-26T17:51:58+00:00 https://ab-science.excalibra.com/fr/interruption-volontaire-des-etudes-cliniques-du-masitinib/ 2021-06-01T05:16:04+00:00 https://ab-science.excalibra.com/results-from-masitinib-study-ab12005-in-pancreatic-cancer-selected-for-presentation-at-the-asco-annual-meeting/ 2021-06-01T05:20:24+00:00 https://ab-science.excalibra.com/fr/conference-virtuelle-le-jeudi-3-juin-2021-suite-a-l-annonce-de-l-interruption-volontaire-des-etudes-cliniques-du-masitinib/ 2021-06-02T13:52:41+00:00 https://ab-science.excalibra.com/webcast-presentation-following-the-voluntary-hold-of-clinical-studies-with-masitinib/ 2021-06-08T07:01:00+00:00 https://ab-science.excalibra.com/fr/presentation-de-la-conference-virtuelle-suite-a-la-suspension-volontaires-des-etudes-cliniques-du-masitinib/ 2021-06-08T07:04:12+00:00 https://ab-science.excalibra.com/fr/resume-de-la-conference-virtuelle-du-3-juin-2021-suite-a-linterruption-volontaire-des-etudes-cliniques-du-masitinib/ 2021-06-08T08:04:33+00:00 https://ab-science.excalibra.com/fr/resultats-etude-ab12005-masitinib-cancer-du-pancreas-reunion-annuelle-2021-asco/ 2021-06-10T17:07:30+00:00 https://ab-science.excalibra.com/summary-of-the-live-webcast-held-on-june-3-2021-following-the-voluntary-hold-in-the-clinical-studies-of-masitinib/ 2021-06-10T17:09:02+00:00 https://ab-science.excalibra.com/fr/accord-avec-des-actionnaires-historiques-en-vue-de-mettre-en-oeuvre-une-strategie-commune-de-valorisation-du-masitinib/ 2021-06-28T18:21:14+00:00 https://ab-science.excalibra.com/fr/resultats-de-l-assemblee-generale-mixte-du-30-juin-2021/ 2021-07-01T06:50:05+00:00 https://ab-science.excalibra.com/fr/retransmission-de-lassemblee-generale-mixte-du-30-juin-2021/ 2021-07-01T16:59:52+00:00 https://ab-science.excalibra.com/fr/validation-du-plan-de-gestion-des-risques-par-l-ansm-en-vue-de-la-reprise-des-inclusions-en-france/ 2021-07-12T06:19:03+00:00 https://ab-science.excalibra.com/fr/publication-nouvelles-donnees-survie-masitinib-prolonge-la-survie-dans-la-sla-de-25-mois/ 2021-07-19T16:55:13+00:00 https://ab-science.excalibra.com/fr/publication-dans-la-revue-de-renommee-mondiale-science-confirmant-le-potentiel-du-masitinib-comme-traitement-de-la-covid-19-avec-une-activite-antivirale-contre-le-sars-cov-2-et-tous-ses-variants-teste/ 2021-07-20T16:18:03+00:00 https://ab-science.excalibra.com/fr/presentation-des-resultats-de-phase-3-de-letude-ab09004-dans-la-maladie-dalzheimer-a-la-alzheimers-association-international-conference-aaic/ 2021-07-22T16:14:37+00:00 https://ab-science.excalibra.com/fr/les-resultats-de-letude-de-phase-3-dans-la-maladie-dalzheimer-ont-ete-presentes-a-la-alzheimers-association-international-conference-aaic/ 2021-07-29T16:12:12+00:00 https://ab-science.excalibra.com/fr/communique-de-questions-reponses-faisant-suite-au-communique-du-28-juin-dernier-relatif-a-la-signature-dun-accord-avec-des-actionnaires-historiques/ 2021-08-06T17:06:10+00:00 https://ab-science.excalibra.com/fr/publication-dun-mecanisme-pathogene-declenche-par-les-mastocytes-dans-la-moelle-epiniere-de-la-sla-qui-peut-etre-cible-par-le-masitinib/ 2021-08-19T15:55:31+00:00 https://ab-science.excalibra.com/fr/premiere-autorisation-de-reprise-des-inclusions-dans-letude-de-phase-3-du-masitinib-dans-la-sla/ 2021-08-23T17:45:44+00:00 https://ab-science.excalibra.com/fr/seconde-autorisation-portant-sur-la-reprise-des-inclusions-dans-letude-de-phase-3-du-masitinib-dans-la-mastocytose/ 2021-08-25T16:48:34+00:00 https://ab-science.excalibra.com/fr/les-dernieres-donnees-cliniques-de-survie-a-long-terme-dans-la-sla-seront-presentees-au-colloque-international-2021-de-la-sla-et-des-maladies-du-motoneurone/ 2021-09-02T15:58:03+00:00 https://ab-science.excalibra.com/fr/les-resultats-de-letude-ab12003-du-masitinib-dans-le-cancer-de-la-prostate-ont-ete-presentes-lors-du-congres-annuel-2021-de-lamerican-urological-association/ 2021-09-13T16:06:33+00:00 https://ab-science.excalibra.com/fr/nouvelles-autorisations-portant-sur-la-reprise-des-inclusions-des-etudes-de-phase-3-du-masitinib/ 2021-09-14T16:04:41+00:00 https://ab-science.excalibra.com/fr/autorisation-de-reprise-des-inclusions-de-patients-dans-letude-de-phase-2-du-masitinib-dans-la-covid-19/ 2021-09-16T17:35:24+00:00 https://ab-science.excalibra.com/fr/un-resume-des-resultats-de-survie-a-long-terme-du-masitinib-dans-la-sla-a-ete-selectionne-pour-une-presentation-lors-de-la-reunion-annuelle-de-la-societe-espagnole-de-neurologie/ 2021-09-20T17:19:40+00:00 https://ab-science.excalibra.com/fr/ab-science-a-recu-lapprobation-de-lautorite-de-sante-canadienne-pour-initier-une-etude-de-phase-i-ii-avec-sa-molecule-ab8939-dans-le-traitement-de-la-leucemie-myeloide-aigue/ 2021-09-22T16:10:47+00:00 https://ab-science.excalibra.com/ab-science-receives-health-canada-approval-letter-to-commence-phase-i-ii-trial-of-ab8939-in-the-treatment-of-acute-myeloid-leukemia/ 2021-09-22T16:11:48+00:00 https://ab-science.excalibra.com/fr/la-food-and-drug-administration-fda-americaine-autorise-conduite-etude-de-phase-3-masitinib-ab19001/ 2021-09-23T13:50:48+00:00 https://ab-science.excalibra.com/fr/ab-science-a-recu-lautorisation-dinitier-une-seconde-etude-de-phase-2-dans-le-traitement-de-la-covid-19/ 2021-09-28T17:26:58+00:00 https://ab-science.excalibra.com/ab-science-receives-regulatory-authorization-to-commence-a-second-phase-2-covid-19-study/ 2021-09-28T17:27:18+00:00 https://ab-science.excalibra.com/fr/resultats-financiers-semestriels-au-30-juin-2021-et-point-sur-les-activites-dab-science/ 2021-09-30T17:21:47+00:00 https://ab-science.excalibra.com/revenues-for-the-first-half-of-2021-and-update-on-ab-sciences-activities/ 2021-09-30T17:21:55+00:00 https://ab-science.excalibra.com/fr/ab-science-recoit-lautorisation-de-la-fda-pour-initier-le-programme-de-developpement-clinique-du-masitinib-dans-le-syndrome-dactivation-des-mastocytes-mcas/ 2021-10-04T16:14:58+00:00 https://ab-science.excalibra.com/ab-science-receives-fda-authorization-to-start-clinical-development-program-of-masitinib-in-mast-cell-activation-syndrome-mcas/ 2021-10-04T16:15:07+00:00 https://ab-science.excalibra.com/fr/ab-science-obtient-lautorisation-de-lansm-dinitier-une-etude-avec-la-molecule-ab8939-dans-le-traitement-de-la-leucemie-myeloide-aigue-lma/ 2021-10-18T16:15:00+00:00 https://ab-science.excalibra.com/ab-science-granted-authorization-from-the-french-health-authority-ansm-to-initiate-a-study-of-ab8939-in-the-treatment-of-acute-myeloid-leukemia-aml/ 2021-10-18T16:15:08+00:00 https://ab-science.excalibra.com/fr/ab-science-recoit-lautorisation-de-la-fda-de-reprendre-le-recrutement-des-patients-dans-letude-confirmatoire-de-phase-3-du-masitinib-ab19001-chez-les-patients-atteints-de-sla/ 2021-11-18T19:42:26+00:00 https://ab-science.excalibra.com/ab-science-received-authorization-from-the-fda-to-resume-patient-enrollment-in-the-confirmatory-phase-3-study-of-masitinib-ab19001-in-patients-with-als/ 2021-11-18T19:42:33+00:00 https://ab-science.excalibra.com/fr/ab-science-recoit-lautorisation-de-la-fda-pour-initier-une-etude-de-phase-i-ii-avec-la-molecule-ab8939-dans-le-traitement-de-la-leucemie-myeloide-aigue/ 2021-11-22T17:22:14+00:00 https://ab-science.excalibra.com/ab-science-received-fda-authorization-to-initiate-phase-1-ii-trial-of-ab8939-in-the-treatment-of-acute-myeloid-leukemia/ 2021-11-22T17:22:22+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-le-recrutement-du-premier-patient-dans-letude-de-phase-2-evaluant-lactivite-antivirale-du-masitinib-contre-le-virus-sars-cov-2-covid-19/ 2021-11-29T20:01:58+00:00 https://ab-science.excalibra.com/ab-science-announces-dosing-of-first-patient-in-phase-2-trial-of-masitinibs-antiviral-activity-against-the-sars-cov-2-covid-19-virus/ 2021-11-29T20:02:04+00:00 https://ab-science.excalibra.com/ab-science-granted-authorization-to-initiate-confirmatory-phase-iii-trial-of-masitinib-in-progressive-forms-of-multiple-sclerosis-by-the-french-health-authority-ansm/ 2022-01-03T17:15:34+00:00 https://ab-science.excalibra.com/fr/ab-science-a-recu-lautorisation-de-lansm-pour-initier-une-etude-confirmatoire-de-phase-iii-avec-le-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques/ 2022-01-06T16:22:02+00:00 https://ab-science.excalibra.com/ab-science-granted-authorization-to-initiate-phase-ii-study-in-patients-with-severe-mast-cell-activation-syndrome-by-the-french-health-authority-ansm/ 2022-01-19T17:05:29+00:00 https://ab-science.excalibra.com/ab-science-granted-authorization-to-initiate-confirmatory-phase-iii-trial-of-masitinib-in-progressive-forms-of-multiple-sclerosis-by-the-swedish-medical-products-agency/ 2022-02-02T17:32:48+00:00 https://ab-science.excalibra.com/fr/ab-science-a-recu-lautorisation-de-lansm-pour-initier-une-etude-de-phase-ii-chez-les-patients-atteints-du-syndrome-dactivation-des-mastocytes-severe/ 2022-02-02T17:55:16+00:00 https://ab-science.excalibra.com/fr/ab-science-a-recu-lautorisation-de-lagence-de-sante-suedoise-pour-initier-une-etude-confirmatoire-de-phase-iii-avec-le-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaque/ 2022-02-02T17:56:07+00:00 https://ab-science.excalibra.com/ab-science-to-present-on-its-amyotrophic-lateral-sclerosis-als-development-program-at-the-2022-als-drug-development-summit/ 2022-02-07T17:15:34+00:00 https://ab-science.excalibra.com/fr/ab-science-presentera-son-programme-de-developpement-dans-la-sclerose-laterale-amyotrophique-sla-lors-de-ledition-2022-du-als-drug-development-summit/ 2022-02-07T17:18:06+00:00 https://ab-science.excalibra.com/clarification-following-the-february-11-2022-public-hearing-of-the-enforcement-committee-of-the-french-market-regulator-amf/ 2022-02-12T19:51:47+00:00 https://ab-science.excalibra.com/fr/mise-au-point-suite-a-la-seance-publique-du-11-fevrier-2022-de-la-commission-des-sanctions-de-lautorite-des-marches-financiers-amf/ 2022-02-12T19:53:12+00:00 https://ab-science.excalibra.com/health-canada-has-granted-authorization-to-file-a-new-drug-submission-for-masitinib-in-the-treatment-of-als-under-the-notice-of-compliance-with-conditions-noc-c-policy/ 2022-02-21T16:49:53+00:00 https://ab-science.excalibra.com/fr/autorisation-de-health-canada-pour-soumettre-une-demande-de-mise-sur-le-marche-du-masitinib-dans-le-traitement-de-la-sla-sous-le-statut-noc-c-notice-of-compliance-with-conditions/ 2022-02-21T16:50:46+00:00 https://ab-science.excalibra.com/fr/publication-de-letude-clinique-pivot-de-phase-3-du-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques-dans-la-revue-neurology-neuroimmunology-neuroinflammation/ 2022-02-22T17:10:12+00:00 https://ab-science.excalibra.com/fr/ab-science-tiendra-une-conference-virtuelle-le-28-fevrier-2022-sur-la-demande-denregistrement-du-masitinib-dans-le-traitement-sla-au-canada-ainsi-que-sur-son-programme-clinique-dans-toutes-les-indi/ 2022-02-24T17:10:02+00:00 https://ab-science.excalibra.com/fr/financement-de-85-millions-de-dollars-us-sous-forme-dobligations-convertibles-en-actions/ 2022-02-28T07:02:31+00:00 https://ab-science.excalibra.com/fr/presentation-de-la-conference-virtuelle-sur-la-demande-denregistrement-du-masitinib-dans-le-traitement-de-la-sla-au-canada-ainsi-que-sur-le-programme-clinique-dab-science-dans-toutes-les-i/ 2022-02-28T18:40:41+00:00 https://ab-science.excalibra.com/fr/communication-dab-science-a-la-suite-de-la-decision-de-la-commission-des-sanctions-de-lautorite-des-marches-financiers/ 2022-03-29T17:59:44+00:00 https://ab-science.excalibra.com/fr/recommandation-favorable-du-comite-independant-de-revue-des-donnees-de-poursuivre-letude-de-phase-2-evaluant-le-masitinib-en-combinaison-avec-lisoquercetine-dans-le-traitement-du-cov/ 2022-04-28T06:03:58+00:00 https://ab-science.excalibra.com/annual-financial-results-as-of-31-december-2021/ 2022-04-29T16:31:58+00:00 https://ab-science.excalibra.com/fr/resultats-financiers-annuels-au-31-decembre-2021/ 2022-04-29T16:32:26+00:00 https://ab-science.excalibra.com/ab-science-announces-that-health-canada-has-started-the-review-of-new-drug-submission-for-masitinib-in-the-treatment-of-als/ 2022-05-26T20:50:41+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-que-health-canada-a-demarre-la-revue-du-dossier-denregistrement-du-masitinib-dans-le-traitement-de-la-sla/ 2022-05-26T20:51:12+00:00 https://ab-science.excalibra.com/publication-of-results-from-the-positive-study-of-masitinib-in-severe-asthma-uncontrolled-by-oral-corticosteroids-in-journal-of-asthma-and-allergy/ 2022-06-07T15:47:40+00:00 https://ab-science.excalibra.com/fr/publication-des-resultats-de-letude-positive-du-masitinib-dans-lasthme-severe-non-controle-par-les-corticosteroides-oraux-dans-la-revue-journal-of-asthma-and-allergy/ 2022-06-07T15:48:15+00:00 https://ab-science.excalibra.com/ab-science-announces-that-it-has-filed-an-application-for-conditional-marketing-authorization-to-ema-for-masitinib-in-the-treatment-of-als/ 2022-08-24T17:09:52+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-avoir-depose-une-demande-dautorisation-de-mise-sur-le-marche-conditionnelle-aupres-de-lema-pour-le-masitinib-dans-le-traitement-de-la-sla/ 2022-08-24T17:11:10+00:00 https://ab-science.excalibra.com/positive-recommendation-of-the-data-and-safety-monitoring-board-to-continue-the-phase-2-study-evaluating-the-antiviral-activity-of-masitinib-in-covid-19/ 2022-09-14T16:23:01+00:00 https://ab-science.excalibra.com/fr/recommandation-favorable-du-comite-independant-de-revue-des-donnees-de-poursuivre-letude-de-phase-2-evaluant-lactivite-antivirale-du-masitinib-dans-le-traitement-du-covid-19/ 2022-09-14T16:23:33+00:00 https://ab-science.excalibra.com/revenues-for-the-first-half-of-2022-and-update-on-ab-sciences-activities/ 2022-09-30T16:41:18+00:00 https://ab-science.excalibra.com/fr/resultats-financiers-semestriels-au-30-juin-2022-et-point-sur-les-activites-dab-science/ 2022-09-30T16:43:14+00:00 https://ab-science.excalibra.com/ab-science-receives-first-agencies-authorizations-to-initiate-confirmatory-phase-3-clinical-study-with-masitinib-in-the-treatment-of-alzheimers-disease/ 2022-10-10T16:06:14+00:00 https://ab-science.excalibra.com/fr/ab-science-a-recu-les-premieres-autorisations-reglementaires-pour-initier-une-etude-clinique-confirmatoire-de-phase-3-avec-le-masitinib-dans-le-traitement-de-la-maladie-dalzheimer/ 2022-10-10T16:06:38+00:00 https://ab-science.excalibra.com/ab-science-receives-u-s-food-and-drug-administration-fda-authorization-to-initiate-confirmatory-phase-3-clinical-study-with-masitinib-in-the-treatment-of-alzheimers-disease/ 2022-11-21T17:11:04+00:00 https://ab-science.excalibra.com/fr/ab-science-a-recu-lapprobation-de-la-food-and-drug-administration-fda-americaine-pour-initier-une-etude-confirmatoire-de-phase-3-avec-le-masitinib-dans-le-traitement-de-la-maladie-d/ 2022-11-21T17:11:33+00:00 https://ab-science.excalibra.com/fr/ab-science-a-recu-un-avis-dinsuffisance-de-lagence-health-canada-pour-le-masitinib-dans-la-sclerose-laterale-amyotrophique/ 2022-12-13T17:10:08+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-le-tirage-de-la-premiere-tranche-de-6-millions-deuros-dans-le-cadre-de-son-contrat-de-financement-avec-la-banque-europeenne-dinvestissement/ 2022-12-22T17:15:02+00:00 https://ab-science.excalibra.com/fr/le-masitinib-recoit-la-designation-de-medicament-orphelin-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-en-suisse/ 2022-12-27T18:06:41+00:00 https://ab-science.excalibra.com/fr/ab-science-a-recu-lapprobation-de-la-food-and-drug-administration-fda-americaine-pour-initier-letude-confirmatoire-de-phase-3-avec-le-masitinib-dans-le-traitement-des-formes-progre/ 2022-12-29T17:11:11+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-le-tirage-de-la-seconde-tranche-de-6-millions-deuros-dans-le-cadre-de-son-contrat-de-financement-avec-la-banque-europeenne-dinvestissement/ 2023-02-08T11:59:01+00:00 https://ab-science.excalibra.com/fr/publication-de-letude-clinique-pivot-de-phase-3-avec-le-masitinib-dans-la-maladie-dalzheimer-dans-la-revue-alzheimers-research-therapy/ 2023-02-28T08:38:55+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-une-premiere-reponse-complete-de-la-moelle-osseuse-chez-un-patient-atteint-de-leucemie-myeloide-aigue-refractaire-en-rechute-a-tres-faible-dose-dans-son-essai-clinique-de-phase-i/ 2023-03-13T17:11:41+00:00 https://ab-science.excalibra.com/fr/ab-science-tiendra-une-conference-virtuelle-sur-sa-plateforme-de-destabilisateurs-de-microtubules-le-jeudi-16-mars-2023-de-18h-a-19h/ 2023-03-15T17:07:51+00:00 https://ab-science.excalibra.com/fr/conference-virtuelle-ab-science-plateforme-de-destabilisateurs-de-microtubules/ 2023-03-16T18:08:52+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-avoir-repondu-aux-questions-au-d120-de-la-procedure-ema-de-demande-dautorisation-conditionnelle-du-masitinib-dans-la-sclerose-laterale-amyotrophique-et-precise-le-nouveau-c/ 2023-04-04T16:14:51+00:00 https://ab-science.excalibra.com/fr/les-resultats-du-masitinib-dans-la-sla-ont-ete-selectionnes-pour-une-presentation-scientifique-a-la-reunion-annuelle-2023-de-laan-et-incluent-lanalyse-de-la-survie-a-long-terme-et-u/ 2023-04-12T16:27:13+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-lobtention-dun-brevet-sur-le-masitinib-au-japon-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-renforcant-ainsi-la-position-de-la-societe-en-matiere-de/ 2023-04-18T17:01:28+00:00 https://ab-science.excalibra.com/fr/mise-en-place-dune-nouvelle-strategie-et-lancement-dune-augmentation-de-capital/ 2023-04-21T20:23:41+00:00 https://ab-science.excalibra.com/fr/succes-de-laugmentation-de-capital-par-placement-prive-pour-un-montant-de-15-millions-deuros/ 2023-04-24T06:10:57+00:00 https://ab-science.excalibra.com/fr/presentation-sur-le-masitinib-dans-la-sla-a-la-reunion-annuelle-2023-de-laan/ 2023-04-27T17:41:04+00:00 https://ab-science.excalibra.com/fr/resume-de-la-presentation-dans-la-sla-a-la-reunion-annuelle-2023-de-laan/ 2023-04-27T18:43:29+00:00 https://ab-science.excalibra.com/fr/resultats-financiers-annuels-au-31-decembre-2022/ 2023-04-28T16:44:13+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-que-health-canada-a-repris-la-revue-du-dossier-denregistrement-du-masitinib-dans-la-sclerose-laterale-amyotrophique-suite-a-lexamen-preliminaire-de-la-reponse-sou/ 2023-05-09T16:09:27+00:00 https://ab-science.excalibra.com/fr/ab-science-resume-les-messages-cles-de-sa-participation-a-une-table-ronde-lors-du-als-drug-development-summit-2023/ 2023-05-17T18:17:40+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-la-tenue-de-son-assemblee-generale-mixte-annuelle-le-30-juin-2023/ 2023-05-30T16:43:01+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-la-delivrance-dun-brevet-canadien-pour-le-masitinib-dans-le-traitement-de-la-sla-avec-une-protection-jusquen-2037/ 2023-06-01T16:05:19+00:00 https://ab-science.excalibra.com/fr/ab-science-recoit-un-avis-dacceptation-pour-un-brevet-europeen-pour-le-masitinib-dans-le-traitement-du-cancer-de-la-prostate-metastatique-hormono-resistant-mcrpc/ 2023-06-26T16:16:33+00:00 https://ab-science.excalibra.com/fr/mise-au-point-sur-le-calendrier-de-lema-concernant-lexamen-de-la-demande-dautorisation-de-mise-sur-le-marche-du-masitinib-dans-la-sla/ 2023-09-18T16:08:13+00:00 https://ab-science.excalibra.com/fr/resultats-financiers-semestriels-au-30-juin-2023-et-point-sur-les-activites-dab-science/ 2023-09-29T17:51:55+00:00 https://ab-science.excalibra.com/fr/le-developpement-clinique-du-masitinib-dans-la-drepanocytose-fait-partie-des-19-projets-laureats-dans-le-cadre-du-6eme-appel-a-projet-rhu/ 2023-11-27T07:16:54+00:00 https://ab-science.excalibra.com/fr/ab-science-tiendra-une-conference-virtuelle-le-jeudi-30-novembre-2023-pour-presenter-le-programme-de-developpement-clinique-du-masitinib-dans-la-drepanocytose/ 2023-11-28T18:25:17+00:00 https://ab-science.excalibra.com/fr/conference-virtuelle-ab-science-le-masitinib-dans-la-drepanocytose/ 2023-11-30T16:49:36+00:00 https://ab-science.excalibra.com/fr/ab-science-recoit-un-avis-dacceptation-pour-le-brevet-europeen-couvrant-le-masitinib-jusquen-2036-dans-le-traitement-de-la-mastocytose/ 2024-01-15T17:09:30+00:00 https://ab-science.excalibra.com/fr/ab-science-fait-le-point-sur-la-demande-dautorisation-de-mise-sur-le-marche-du-masitinib-dans-la-sclerose-laterale-amyotrophique-aupres-de-lagence-europeenne-des-medicaments/ 2024-01-26T17:03:00+00:00 https://ab-science.excalibra.com/fr/conference-virtuelle-le-lundi-4-mars-2024-de-18h30-a-19h30/ 2024-03-01T17:21:08+00:00 https://ab-science.excalibra.com/fr/deux-societes-danalyse-financiere-initient-la-couverture-du-titre-ab-science/ 2024-03-06T19:23:12+00:00 https://ab-science.excalibra.com/fr/conference-virtuelle-ab-science-du-4-mars-2024/ 2024-03-07T10:18:36+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-que-sante-canada-a-emis-un-avis-de-non-conformite-retrait-anc-r-pour-le-masitinib-dans-la-sla/ 2024-03-07T10:32:53+00:00 https://ab-science.excalibra.com/fr/resume-de-la-conference-virtuelle-sur-le-developpement-dab-science-qui-sest-tenue-le-4-mars-2024/ 2024-03-07T14:23:08+00:00 https://ab-science.excalibra.com/fr/de-nouvelles-recherches-montrent-que-le-masitinib-limite-les-dommages-neuronaux-dans-un-modele-de-maladie-neurodegenerative-dorigine-neuroimmune/ 2024-03-13T12:00:54+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-que-sante-canada-a-juge-admissible-la-demande-de-reexamen-du-masitinib-dans-sla/ 2024-04-03T16:11:58+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-un-leger-decalage-de-la-publication-de-son-rapport-financier-annuel-2023/ 2024-04-30T16:59:56+00:00 https://ab-science.excalibra.com/fr/la-cour-dappel-de-paris-confirme-la-mise-hors-de-cause-du-president-directeur-general-dab-science-alain-moussy-et-diminue-le-montant-de-la-sanction-imposee-a-ab-science/ 2024-05-02T17:17:11+00:00 https://ab-science.excalibra.com/fr/une-nouvelle-publication-dans-la-revue-medicale-muscle-nerve-valide-lutilisation-du-declin-du-score-alsfr-s-%ce%b4fs-pour-le-design-des-etudes-cliniques-et-le-choix-de-traitement-des-pati/ 2024-05-07T16:06:58+00:00 https://ab-science.excalibra.com/fr/resultats-financiers-annuels-au-31-decembre-2023/ 2024-05-15T18:19:11+00:00 https://ab-science.excalibra.com/fr/communique-rectificatif-sur-les-comptes-consolides-au-31-decembre-2023/ 2024-05-17T15:59:49+00:00 https://ab-science.excalibra.com/fr/ab-science-fait-le-point-sur-la-demande-dautorisation-de-mise-sur-le-marche-conditionnelle-du-masitinib-dans-la-sla/ 2024-05-29T16:05:53+00:00 https://ab-science.excalibra.com/fr/resume-de-la-conference-virtuelle-qui-sest-tenue-le-30-mai-2024-faisant-le-point-sur-la-demande-dautorisation-de-mise-sur-le-marche-conditionnelle-du-masitinib-dans-la-sla/ 2024-05-31T14:33:28+00:00 https://ab-science.excalibra.com/fr/conference-virtuelle-ab-science-du-30-mai-2024/ 2024-06-03T09:30:06+00:00 https://ab-science.excalibra.com/fr/agm-du-26-juin-2024-document-de-questions-reponses/ 2024-06-26T14:32:42+00:00 https://ab-science.excalibra.com/fr/ab-science-fait-le-point-sur-la-demande-dautorisation-de-mise-sur-le-marche-conditionnelle-du-masitinib-dans-la-sla-2/ 2024-06-28T10:33:06+00:00 https://ab-science.excalibra.com/fr/resultats-positifs-de-letude-de-phase-2-evaluant-le-masitinib-dans-la-covid-19/ 2024-07-08T05:52:41+00:00 https://ab-science.excalibra.com/fr/ab-science-fait-aujourdhui-le-point-sur-le-developpement-du-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques-suite-a-la-conference-ectrims-2024/ 2024-09-23T15:48:30+00:00 https://ab-science.excalibra.com/fr/ab-science-fait-aujourdhui-le-point-sur-le-programme-microtubule-ab8939/ 2024-09-26T06:31:20+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-une-augmentation-de-capital-de-50-millions-deuros/ 2024-09-30T06:30:57+00:00 https://ab-science.excalibra.com/ab-science-announces-a-slight-delay-in-the-publication-of-its-2024-half-year-financial-report/ 2024-09-30T16:34:20+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-un-leger-decalage-de-la-publication-de-son-rapport-financier-du-premier-semestre-2024/ 2024-09-30T16:35:58+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-avoir-realise-le-reglement-livraison-de-sa-derniere-augmentation-de-capital-de-50-millions-deuros/ 2024-10-09T06:20:12+00:00 https://ab-science.excalibra.com/ab-science-announces-the-completion-of-settlement-and-delivery-of-its-latest-capital-increase-of-5-0-millions-euros/ 2024-10-09T06:22:39+00:00 https://ab-science.excalibra.com/revenues-for-the-first-half-of-2024-and-update-on-ab-sciences-activities/ 2024-10-10T06:27:01+00:00 https://ab-science.excalibra.com/fr/resultats-financiers-semestriels-au-30-juin-2024-et-point-sur-les-activites-dab-science/ 2024-10-10T06:29:17+00:00 https://ab-science.excalibra.com/ab-science-provides-an-update-on-the-application-for-conditional-marketing-authorisation-of-masitinib-in-als-3/ 2024-10-17T17:26:55+00:00 https://ab-science.excalibra.com/fr/ab-science-fait-le-point-sur-la-demande-dautorisation-de-mise-sur-le-marche-conditionnelle-du-masitinib-dans-la-sla-3/ 2024-10-17T17:27:19+00:00 https://ab-science.excalibra.com/ab-science-receives-notice-of-allowance-for-european-patent-covering-masitinib-until-2040-in-the-treatment-of-sickle-cell-disease/ 2024-10-28T16:45:52+00:00 https://ab-science.excalibra.com/fr/ab-science-recoit-un-avis-dacceptation-pour-le-brevet-europeen-couvrant-jusquen-2040-le-masitinib-dans-le-traitement-de-la-drepanocytose/ 2024-10-28T16:46:13+00:00 https://ab-science.excalibra.com/live-webcast-on-monday-december-16-2024-from-5-30pm-to-6-30pm-cet/ 2024-12-11T17:03:41+00:00 https://ab-science.excalibra.com/fr/conference-virtuelle-le-lundi-16-decembre-2024-de-17h30-a-18h30/ 2024-12-11T17:04:48+00:00 https://ab-science.excalibra.com/ab-science-webcast-of-december-16-2024/ 2024-12-16T18:13:30+00:00 https://ab-science.excalibra.com/fr/conference-virtuelle-du-16-decembre-2024/ 2024-12-16T18:14:01+00:00 https://ab-science.excalibra.com/fr/summary-of-the-webcast-held-on-december-16-2024/ 2024-12-17T18:03:21+00:00 https://ab-science.excalibra.com/summary-of-the-webcast-held-on-december-16-2024/ 2024-12-17T18:08:21+00:00 https://ab-science.excalibra.com/fr/resume-de-la-conference-virtuelle-du-16-decembre-2024/ 2024-12-17T18:09:01+00:00 https://ab-science.excalibra.com/fr/ab-science-participera-a-la-conference-investisseurs-biomed-forum/ 2025-01-22T18:03:49+00:00 https://ab-science.excalibra.com/ab-science-will-participate-in-the-biomed-forum-investors-conference/ 2025-01-23T08:31:04+00:00 https://ab-science.excalibra.com/live-webcast-on-tuesday-january-28-2025-from-5-30pm-to-6-45pm-cet/ 2025-01-24T16:58:36+00:00 https://ab-science.excalibra.com/fr/conference-virtuelle-le-mardi-28-janvier-2025-de-17h30-a-18h45/ 2025-01-24T16:59:19+00:00 https://ab-science.excalibra.com/fr/conference-virtuelle-du-28-janvier-2025/ 2025-01-29T16:24:23+00:00 https://ab-science.excalibra.com/fr/resume-de-la-conference-virtuelle-du-28-janvier-2025/ 2025-01-29T18:09:07+00:00 https://ab-science.excalibra.com/fr/un-article-de-la-revue-de-reference-life-sciences-magazine-presente-le-masitinib-dab-science-et-son-investigateur-principal-de-phase-3-le-neurologue-patrick-vermersch/ 2025-03-04T07:40:00+00:00 https://ab-science.excalibra.com/fr/ab-science-recoit-un-avis-dacceptation-pour-le-brevet-americain-courant-jusquen-2040-le-masitinib-dans-le-traitement-de-la-drepanocytose/ 2025-04-14T16:06:17+00:00 https://ab-science.excalibra.com/fr/la-molecule-ab8939-obtient-la-designation-de-medicament-orphelin-dans-lunion-europeenne-aupres-de-lagence-europeenne-des-medicaments-dans-le-traitement-de-la-leucemie-myeloide-aigue/ 2025-04-23T17:02:01+00:00 https://ab-science.excalibra.com/fr/ab-science-publiera-son-rapport-financier-annuel-2024-le-vendredi-9-mai-2025/ 2025-05-01T08:12:06+00:00 https://ab-science.excalibra.com/fr/ab-science-presentera-lors-de-la-reunion-annuelle-de-lencals-en-2025-de-nouvelles-donnees-issues-du-programme-de-developpement-clinique-du-masitinib-dans-la-sla/ 2025-05-05T16:02:37+00:00 https://ab-science.excalibra.com/fr/resultats-financiers-annuels-au-31-decembre-2024/ 2025-05-12T06:16:02+00:00 https://ab-science.excalibra.com/fr/cnews-interview-d-alain-moussy/ 2025-05-13T09:01:43+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-une-nouvelle-publication-dans-la-revue-scientifique-plos-one/ 2025-05-15T06:12:20+00:00 https://ab-science.excalibra.com/ab-science-receives-chinese-patent-protecting-masitinib-in-the-treatment-of-covid-19-until-2041/ 2025-05-19T06:00:43+00:00 https://ab-science.excalibra.com/fr/ab-science-recoit-un-brevet-chinois-protegeant-le-masitinib-dans-le-traitement-du-covid-19-jusquen-2041/ 2025-05-19T06:02:24+00:00 https://ab-science.excalibra.com/ab-science-announces-the-successful-completion-of-a-eur-1-8-million-private-placement/ 2025-05-20T05:51:21+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-le-succes-dun-placement-prive-de-18-millions-deuros/ 2025-05-20T05:51:21+00:00 https://ab-science.excalibra.com/ab-science-announces-the-settlement-delivery-of-its-latest-capital-increase-for-e1-8-million/ 2025-05-23T05:44:49+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-avoir-realise-le-reglement-livraison-de-sa-derniere-augmentation-de-capital-pour-18-million-deuros/ 2025-05-23T05:46:26+00:00 https://ab-science.excalibra.com/ab-science-announces-ema-approval-of-masivet-shelf-life-extension-to-4-years/ 2025-06-09T05:57:46+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-lapprobation-par-lema-de-la-prolongation-de-la-duree-de-conservation-de-masivet-a-4-ans/ 2025-06-09T05:59:34+00:00 https://ab-science.excalibra.com/ab-science-announces-issuance-of-a-canadian-patent-protecting-the-composition-of-matter-of-ab8939-including-its-use-in-the-treatment-of-acute-myeloid-leukemia-with-protection-until-2036/ 2025-06-12T05:53:45+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-la-delivrance-dun-brevet-canadien-protegeant-la-composition-de-matiere-dab8939-y-compris-son-utilisation-dans-le-traitement-de-la-leucemie-myeloide-aigue-avec-un/ 2025-06-12T05:55:10+00:00 https://ab-science.excalibra.com/new-peer-reviewed-data-provide-strong-evidence-supporting-masitinib-potential-for-the-treatment-of-alzheimers-disease/ 2025-06-23T06:13:31+00:00 https://ab-science.excalibra.com/fr/de-nouvelles-donnees-evaluees-par-des-pairs-apportent-des-preuves-solides-du-potentiel-du-masitinib-dans-le-traitement-de-la-maladie-dalzheimer/ 2025-06-23T06:15:25+00:00 https://ab-science.excalibra.com/ab-science-provides-an-update-on-the-renegotiation-of-loan-repayment-terms-with-its-financial-creditors/ 2025-06-30T06:01:21+00:00 https://ab-science.excalibra.com/fr/ab-science-fait-un-point-sur-la-renegociation-des-modalites-de-remboursement-de-ses-emprunts-avec-ses-creanciers-financiers/ 2025-06-30T06:04:49+00:00 https://ab-science.excalibra.com/fr/le-masitinib-recoit-lautorisation-de-la-fda-et-de-lema-pour-letude-confirmatoire-de-phase-3-dans-le-cancer-de-la-prostate-metastatique-hormono-resistant-avec-une-selection-des-patients-b/ 2025-07-04T05:55:35+00:00 https://ab-science.excalibra.com/masitinib-receives-fda-and-ema-authorization-for-confirmatory-phase-3-trial-in-metastatic-castrate-resistant-prostate-cancer-with-biomarker-driven-patient-selection-targeting-population-most-likely-t/ 2025-07-04T05:56:11+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-le-succes-dun-placement-prive-de-1925-millions-deuros/ 2025-07-08T06:03:10+00:00 https://ab-science.excalibra.com/fr/ab-science-a-obtenu-lautorisation-de-plusieurs-pays-europeens-pour-initier-letude-confirmatoire-de-phase-3-avec-le-masitinib-dans-la-sla/ 2025-07-24T05:49:29+00:00 https://ab-science.excalibra.com/fr/ab-science-a-recu-lapprobation-reglementaire-de-pays-europeens-pour-initier-la-troisieme-etape-de-la-phase-i-ii-visant-a-combiner-sa-molecule-ab8939-avec-le-venetoclax-dans-le-traitement-de-l/ 2025-07-30T05:44:02+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-le-succes-dun-placement-prive-denviron-255-millions-deuros/ 2025-08-04T05:50:30+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-un-leger-decalage-de-la-publication-de-son-rapport-financier-du-premier-semestre-2025/ 2025-09-30T16:26:00+00:00 https://ab-science.excalibra.com/fr/resultats-financiers-semestriels-au-30-juin-2025-et-point-sur-les-activites-dab-science/ 2025-10-10T16:08:49+00:00 https://ab-science.excalibra.com/fr/conference-virtuelle-du-16-octobre-2025/ 2025-10-16T18:18:37+00:00 https://ab-science.excalibra.com/fr/ab-science-tiendra-une-conference-virtuelle-le-jeudi-16-octobre-2025-de-14-h-a-15-h-cet-afin-de-faire-le-point-sur-letude-de-phase-1-avec-ab8939/ 2025-10-16T18:19:48+00:00 https://ab-science.excalibra.com/fr/resume-de-la-conference-virtuelle-du-16-octobre-2025/ 2025-10-16T18:52:49+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-le-succes-dun-placement-prive-denviron-28-millions-deuros/ 2025-10-17T05:50:31+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-une-nouvelle-publication-sur-medrxiv-mettant-en-evidence-le-benefice-clinique-du-masitinib-chez-les-patients-atteints-de-sclerose-laterale-amyotrophique-avant-toute-perte-complete-d/ 2025-12-11T17:14:20+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-une-nouvelle-publication-sur-biorxiv-identifiant-ab8939-comme-un-candidat-medicament-prometteur-pour-le-traitement-de-la-leucemie-myeloide-aigue-refractaire-et-potentiellement-dau/ 2025-12-15T17:37:04+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-linitiation-de-la-couverture-de-son-titre-par-maxim-group-avec-un-objectif-de-cours-de-40-euros-par-action/ 2025-12-18T18:20:22+00:00 https://ab-science.excalibra.com/fr/le-brevet-pour-le-masitinib-dans-le-traitement-de-la-drepanocyose-a-ete-officiellement-accorde-aux-etats-unis-avec-une-protection-jusquen-2040/ 2025-12-22T16:51:21+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-un-quatrieme-cas-consecutif-de-reponse-avec-la-combinaison-dab8939-et-du-venetoclax-dans-le-traitement-de-la-leucemie-myeloide-aigue-refractaire-ou-en-rechute-sur-la-base/ 2026-01-07T18:13:27+00:00 https://ab-science.excalibra.com/fr/ab-science-obtient-un-brevet-japonais-pour-lutilisation-du-masitinib-dans-le-traitement-des-formes-progressives-de-la-sclerose-en-plaques-sep-jusquen-2041/ 2026-01-21T16:51:21+00:00 https://ab-science.excalibra.com/fr/ab-science-recoit-un-avis-dautorisation-pour-un-brevet-americain-couvrant-le-masitinib-dans-le-traitement-du-cancer-de-la-prostate-metastatique-hormono-resistant/ 2026-01-29T16:45:38+00:00 https://ab-science.excalibra.com/fr/la-fda-a-accorde-le-statut-de-minor-use-in-major-species-mums-au-masivet/ 2026-02-09T16:49:43+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-lidentification-dun-biomarqueur-plasmatique-marqueur-de-lactivite-du-masitinib-dans-le-traitement-de-la-sla/ 2026-02-24T16:54:10+00:00 https://ab-science.excalibra.com/fr/point-sur-le-programme-de-developpement-clinique-dab-science/ 2026-04-16T17:18:32+00:00 https://ab-science.excalibra.com/fr/nouvelle-publication-sur-medrxiv-demontrant-des-benefices-substantiels-en-termes-de-survie-et-de-qualite-de-vie-preservee-avec-le-masitinib-chez-les-patients-atteints-de-sla/ 2026-04-20T19:31:03+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-un-accord-final-sur-la-renegociation-des-modalites-de-remboursement-de-ses-emprunts-avec-lensemble-de-ses-creanciers-financiers/ 2026-04-27T16:02:22+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-le-succes-dun-placement-prive-de-32-millions-deuros/ 2026-04-29T05:56:44+00:00 https://ab-science.excalibra.com/fr/resultats-financiers-annuels-au-31-decembre-2025/ 2026-05-13T17:34:26+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-que-le-titre-ab-science-continue-detre-couvert-par-maxim-group-avec-un-objectif-de-cours-de-400-e-par-action/ 2026-05-25T16:05:29+00:00 https://ab-science.excalibra.com/fr/stonegate-capital-partners-actualise-sa-couverture-de-laction-ab-science-avec-un-objectif-de-cours-de-425-eur-par-action/ 2026-06-02T16:01:01+00:00 https://ab-science.excalibra.com/fr/ab-science-presentera-lors-du-congres-annuel-2026-de-lencals-les-donnees-de-survie-issues-du-programme-clinique-du-masitinib-dans-la-sla/ 2026-06-09T16:35:07+00:00 https://ab-science.excalibra.com/fr/le-brevet-dab-science-concernant-le-masitinib-dans-le-traitement-du-cancer-de-la-prostate-metastatique-hormono-resistant-a-ete-officiellement-delivre-aux-etats-unis-avec-une-duree-de-protecti/ 2026-06-17T15:48:39+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-lachevement-de-letape-3-de-la-phase-1-evaluant-la-combinaison-dab8939-et-du-venetoclax-dans-le-traitement-de-la-lma-refractaire-ou-en-rechute/ 2026-06-29T05:29:23+00:00 https://ab-science.excalibra.com/fr/ab-science-annonce-le-succes-dun-placement-prive-de-23-millions-deuros/ 2026-07-01T05:57:17+00:00 https://ab-science.excalibra.com/fr/le-conseil-dadministration-dab-science-fait-evoluer-la-gouvernance-afin-dengager-une-nouvelle-etape-du-developpement-de-la-societe/ 2026-07-08T08:44:43+00:00 https://ab-science.excalibra.com/fr/ab-science-fait-le-point-sur-son-programme-clinique-avec-larret-de-certaines-etudes-cliniques-non-prioritaires-en-vue-de-se-concentrer-sur-deux-programmes-cliniques/ 2026-07-10T15:47:53+00:00 https://ab-science.excalibra.com/ab-science-provides-an-update-on-its-clinical-program-suspending-some-non-priority-clinical-trials-to-focus-on-two-clinical-programs/ 2026-08-04T10:46:40+00:00 https://ab-science.excalibra.com/ab-sciences-board-of-directors-is-restructuring-its-governance-to-usher-in-a-new-phase-in-the-companys-development/ 2026-08-04T10:47:30+00:00 https://ab-science.excalibra.com/ab-science-announces-the-successful-completion-of-a-eur-2-3-million-private-placement/ 2026-08-04T10:48:57+00:00 https://ab-science.excalibra.com/ab-science-reports-completion-of-the-step-3-of-phase-1-evaluating-the-combination-of-ab8939-with-venetoclax-for-the-treatment-of-refractory-or-relapsed-aml/ 2026-08-04T10:49:27+00:00 https://ab-science.excalibra.com/ab-science-patent-for-masitinib-in-the-treatment-of-metastatic-castrate-resistant-prostate-cancer-formally-granted-in-the-united-states-with-a-protection-until-2042/ 2026-08-04T10:50:27+00:00 https://ab-science.excalibra.com/ab-science-is-invited-to-present-at-the-2026-encals-annual-meeting-the-survival-data-from-masitinib-clinical-program-in-als/ 2026-08-04T10:50:57+00:00 https://ab-science.excalibra.com/stonegate-capital-partners-updates-its-coverage-of-ab-sciences-stock-with-a-target-price-of-eur-4-25-per-share/ 2026-08-04T10:51:21+00:00 https://ab-science.excalibra.com/ab-science-announces-that-its-stock-continues-to-be-covered-by-maxim-group-with-a-target-price-of-e4-00-per-share/ 2026-08-04T10:52:06+00:00 https://ab-science.excalibra.com/annual-financial-results-as-of-31-december-2025/ 2026-08-04T10:52:43+00:00 https://ab-science.excalibra.com/ab-science-announces-the-successful-completion-of-a-eur-3-2-million-private-placement/ 2026-08-04T10:53:08+00:00 https://ab-science.excalibra.com/ab-science-announces-a-final-agreement-on-the-renegotiation-of-the-repayment-terms-of-its-loans-with-all-of-its-financial-creditors/ 2026-08-04T10:53:29+00:00 https://ab-science.excalibra.com/new-publication-on-medrxiv-demonstrating-substantial-survival-benefits-and-preserved-quality-of-life-with-masitinib-in-als-patients/ 2026-08-04T10:54:20+00:00 https://ab-science.excalibra.com/update-on-clinical-development-program/ 2026-08-04T10:54:43+00:00 https://ab-science.excalibra.com/ab-science-announces-the-identification-of-a-plasma-biomarker-that-indicates-the-activity-of-masitinib-in-treating-als/ 2026-08-04T10:55:07+00:00 https://ab-science.excalibra.com/fda-granted-the-status-of-minor-use-in-major-species-mums-for-masivet/ 2026-08-04T10:55:28+00:00 https://ab-science.excalibra.com/ab-science-receives-notice-of-allowance-for-us-patent-covering-masitinib-in-the-treatment-of-metastatic-castrate-resistant-prostate-cancer/ 2026-08-04T10:56:44+00:00 https://ab-science.excalibra.com/ab-science-receives-japanese-patent-protection-for-the-use-of-masitinib-in-progressive-forms-of-multiple-sclerosis-ms-until-2041/ 2026-08-04T10:57:10+00:00 https://ab-science.excalibra.com/ab-science-reports-fourth-consecutive-case-of-response-from-phase-1-data-for-the-combination-of-ab8939-with-venetoclax-for-the-treatment-of-refractory-or-relapsed-acute-myeloid-leukemia/ 2026-08-04T10:57:40+00:00 https://ab-science.excalibra.com/ab-science-patent-for-masitinib-in-the-treatment-of-sickle-cell-disease-formally-granted-in-the-us-with-a-protection-until-2040/ 2026-08-04T10:58:04+00:00 https://ab-science.excalibra.com/ab-science-announces-the-initiation-of-coverage-of-its-stock-by-maxim-group-with-a-target-price-of-eur-4-0-per-share/ 2026-08-04T11:01:46+00:00 https://ab-science.excalibra.com/ab-science-announces-a-new-publication-on-biorxiv-that-identifies-ab8939-as-a-promising-drug-candidate-for-treating-refractory-acute-myeloid-leukemia-and-potentially-other-cancers/ 2026-08-04T11:02:29+00:00 https://ab-science.excalibra.com/ab-science-announces-new-publication-on-medrxiv-highlighting-clinical-benefit-with-masitinib-in-amyotrophic-lateral-sclerosis-patients-prior-any-complete-loss-of-function/ 2026-08-04T11:02:49+00:00 https://ab-science.excalibra.com/ab-science-announces-the-successful-completion-of-a-2-8-million-euros-private-placement/ 2026-08-04T11:05:07+00:00 https://ab-science.excalibra.com/summary-of-the-virtual-conference-held-on-october-16-2025/ 2026-08-04T11:05:37+00:00 https://ab-science.excalibra.com/ab-science-webcast-of-october-16-2025/ 2026-08-04T11:06:05+00:00 https://ab-science.excalibra.com/ab-science-will-hold-a-virtual-conference-on-thursday-october-16-2025-from-2pm-to-3pm-cet-to-provide-an-update-on-the-phase-1-study-with-ab8939/ 2026-08-04T11:06:45+00:00 https://ab-science.excalibra.com/revenues-for-the-first-half-of-2025-and-update-on-ab-sciences-activities/ 2026-08-04T11:07:08+00:00 https://ab-science.excalibra.com/ab-science-announces-a-slight-delay-in-the-publication-of-its-2025-half-year-financial-report/ 2026-08-04T11:07:29+00:00 https://ab-science.excalibra.com/ab-science-announces-the-successful-completion-of-a-2-55-million-euros-private-placement/ 2026-08-04T11:10:56+00:00 https://ab-science.excalibra.com/ab-science-receives-regulatory-approval-from-european-countries-to-initiate-third-stage-of-phase-i-ii-study-combining-its-molecule-ab8939-with-venetoclax-for-the-treatment-of-aml/ 2026-08-04T11:11:24+00:00 https://ab-science.excalibra.com/ab-science-has-received-approval-from-several-european-countries-to-initiate-the-confirmatory-phase-3-study-of-masitinib-in-als/ 2026-08-04T11:13:08+00:00 https://ab-science.excalibra.com/ab-science-announces-the-successful-completion-of-a-eur-1-925-million-private-placement/ 2026-08-04T11:13:31+00:00 https://ab-science.excalibra.com/ab-science-reports-a-new-publication-in-the-scientific-journal-plos-one/ 2026-08-04T11:16:55+00:00 https://ab-science.excalibra.com/cnews-interview-of-alain-moussy/ 2026-08-04T11:17:29+00:00 https://ab-science.excalibra.com/annual-financial-results-as-of-31-december-2024/ 2026-08-04T11:21:49+00:00 https://ab-science.excalibra.com/ab-science-will-present-new-data-from-masitinib-clinical-program-in-als-in-two-presentations-at-the-2025-encals-annual-meeting/ 2026-08-04T11:22:26+00:00 https://ab-science.excalibra.com/ab-science-will-publish-its-2024-annual-financial-report-on-may-9-2025/ 2026-08-04T11:23:06+00:00 https://ab-science.excalibra.com/european-medicines-agency-has-granted-orphan-drug-designation-in-the-european-union-for-ab8939-in-the-treatment-of-acute-myeloid-leukemia/ 2026-08-04T11:24:22+00:00 https://ab-science.excalibra.com/ab-science-receives-notice-of-allowance-for-unites-states-patent-covering-masitinib-until-2040-in-the-treatment-of-sickle-cell-disease/ 2026-08-04T11:26:02+00:00 https://ab-science.excalibra.com/article-from-the-leading-publication-life-sciences-magazine-featuring-ab-sciences-masitinib-and-its-phase-3-principal-investigator-the-neurologist-patrick-vermersch/ 2026-08-04T11:26:49+00:00 https://ab-science.excalibra.com/summary-of-the-webcast-held-on-january-28-2025/ 2026-08-04T11:27:15+00:00 https://ab-science.excalibra.com/ab-science-webcast-of-january-28-2025/ 2026-08-04T11:27:51+00:00 https://ab-science.excalibra.com/ab-science-announces-the-success-of-a-5-0-million-euros-capital-increase/ 2026-08-04T11:33:04+00:00 https://ab-science.excalibra.com/ab-science-provides-an-update-on-the-microtubule-program-ab8939/ 2026-08-04T11:33:25+00:00 https://ab-science.excalibra.com/ab-science-provides-an-update-on-the-development-of-masitinib-in-progressive-forms-of-multiple-sclerosis-post-ectrims-2024/ 2026-08-04T11:33:46+00:00 https://ab-science.excalibra.com/positive-results-of-the-phase-2-study-evaluating-masitinib-in-covid-19/ 2026-08-04T11:34:58+00:00 https://ab-science.excalibra.com/ab-science-provides-an-update-on-the-application-for-conditional-marketing-authorisation-of-masitinib-in-als-2/ 2026-08-04T11:35:24+00:00 https://ab-science.excalibra.com/june-26-2024-cgm-qa-document/ 2026-08-04T11:35:45+00:00 https://ab-science.excalibra.com/summary-of-the-live-webcast-held-on-may-30-2024-giving-an-update-on-the-application-for-conditional-marketing-authorization-of-masitinib-in-als/ 2026-08-04T11:36:11+00:00 https://ab-science.excalibra.com/ab-science-provides-an-update-on-the-application-for-conditional-marketing-authorisation-of-masitinib-in-als-4/ 2026-08-04T11:37:53+00:00 https://ab-science.excalibra.com/ab-science-webcast-of-may-30-2024/ 2026-08-04T11:38:36+00:00 https://ab-science.excalibra.com/ab-science-provides-an-update-on-the-application-for-conditional-marketing-authorisation-of-masitinib-in-als/ 2026-08-04T11:40:10+00:00 https://ab-science.excalibra.com/corrective-statement-on-the-consolidated-accounts-as-of-december-31-2023/ 2026-08-04T11:40:55+00:00 https://ab-science.excalibra.com/annual-financial-results-as-of-31-december-2023/ 2026-08-04T11:41:45+00:00 https://ab-science.excalibra.com/ab-science-announces-issuance-of-a-european-patent-for-masitinib-in-the-treatment-of-severe-mastocytosis-with-protection-until-2036/ 2026-08-04T11:42:39+00:00 https://ab-science.excalibra.com/a-new-publication-in-the-medical-journal-muscle-nerve-validates-the-use-of-the-rate-of-decline-of-alsfr-s-score-%ce%b4fs-for-the-design-of-clinical-studies-and-the-treatment-choice-for-amyotrophic/ 2026-08-04T11:43:28+00:00 https://ab-science.excalibra.com/the-paris-court-of-appeal-confirms-the-acquittal-of-the-ceo-of-ab-science-alain-moussy-and-reduces-the-amount-of-the-financial-penalty-imposed-on-ab-science/ 2026-08-04T11:44:53+00:00 https://ab-science.excalibra.com/ab-science-announces-a-slight-delay-in-the-publication-of-its-2023-annual-financial-report/ 2026-08-04T11:45:29+00:00 https://ab-science.excalibra.com/ab-science-announces-that-health-canada-has-granted-eligibility-for-reconsideration-request-for-masitinib-in-als/ 2026-08-04T11:46:06+00:00 https://ab-science.excalibra.com/new-research-shows-that-masitinib-limits-neuronal-damage-in-a-model-of-neuroimmune-driven-neurodegenerative-disease/ 2026-08-04T11:46:37+00:00 https://ab-science.excalibra.com/summary-of-the-live-webcast-held-on-march-4-2024-providing-an-update-on-ab-science-development/ 2026-08-04T11:48:14+00:00 https://ab-science.excalibra.com/two-financial-analysis-firms-initiate-coverage-of-ab-science/ 2026-08-04T11:48:46+00:00 https://ab-science.excalibra.com/ab-science-webcast-of-march-4-2024/ 2026-08-04T11:52:30+00:00 https://ab-science.excalibra.com/live-webcast-on-monday-march-4-2024-from-6-30pm-to-7-30pm-cet/ 2026-08-04T11:53:05+00:00 https://ab-science.excalibra.com/ab-science-announces-that-health-canada-has-issued-a-notice-of-non-compliance-withdrawal-non-w-for-masitinib-in-als/ 2026-08-04T11:53:41+00:00 https://ab-science.excalibra.com/ab-science-announces-an-update-in-the-marketing-authorization-application-of-masitinib-in-amyotrophic-lateral-sclerosis-at-the-european-medicines-agency/ 2026-08-04T11:54:12+00:00 https://ab-science.excalibra.com/ab-science-receives-notice-of-allowance-for-european-patent-covering-masitinib-until-2036-in-the-treatment-of-mastocytosis/ 2026-08-04T11:54:42+00:00 https://ab-science.excalibra.com/ab-science-webcast-masitinib-in-sickle-cell-disease/ 2026-08-04T11:55:23+00:00 https://ab-science.excalibra.com/ab-science-will-host-a-live-webcast-on-thursday-november-30-2023-to-present-the-masitinib-development-program-in-sickle-cell-disease/ 2026-08-04T11:56:29+00:00 https://ab-science.excalibra.com/the-clinical-development-of-masitinib-in-sickle-cell-disease-is-among-the-19-winning-projects-under-the-sixth-call-for-hospital-inuversity-research-in-health-rhu/ 2026-08-04T11:57:01+00:00 https://ab-science.excalibra.com/revenues-for-the-first-half-of-2023-and-update-on-ab-sciences-activities/ 2026-08-04T11:58:07+00:00 https://ab-science.excalibra.com/update-on-the-ema-timetable-for-examination-of-the-masitinib-marketing-authorization-application-in-als/ 2026-08-04T11:58:45+00:00 https://ab-science.excalibra.com/ab-science-receives-notice-of-allowance-for-european-patent-covering-masitinib-in-the-treatment-of-metastatic-castrate-refractory-prostate-cancer-mcrpc/ 2026-08-04T12:01:40+00:00 https://ab-science.excalibra.com/ab-science-announces-issuance-of-a-canadian-patent-for-masitinib-in-the-treatment-of-als-with-protection-until-2037/ 2026-08-04T12:03:23+00:00 https://ab-science.excalibra.com/ab-science-to-hold-its-annual-general-meeting-of-shareholders-on-june-30-2023/ 2026-08-04T12:04:10+00:00 https://ab-science.excalibra.com/ab-science-summarizes-key-messages-from-its-participation-to-a-panel-discussion-at-the-2023-als-drug-development-summit/ 2026-08-04T12:04:50+00:00 https://ab-science.excalibra.com/ab-science-announces-that-health-canada-has-resumed-its-review-of-the-new-drug-submission-for-masitinib-in-amyotrophic-lateral-sclerosis-following-issuance-of-a-screening-acceptance-letter/ 2026-08-04T12:05:59+00:00 https://ab-science.excalibra.com/annual-financial-results-as-of-31-december-2022/ 2026-08-04T12:06:48+00:00 https://ab-science.excalibra.com/summary-of-the-presentation-on-masitinib-in-als-delivered-at-2023-aan-annual-meeting/ 2026-08-04T12:08:36+00:00 https://ab-science.excalibra.com/presentation-on-masitinib-in-als-delivered-at-2023-aan-annual-meeting/ 2026-08-04T12:28:52+00:00 https://ab-science.excalibra.com/success-of-the-capital-increase-by-private-placement-for-an-amount-of-15-million-euros/ 2026-08-04T12:29:27+00:00 https://ab-science.excalibra.com/implementation-of-a-new-strategy-and-launch-of-a-capital-increase/ 2026-08-04T12:30:05+00:00 https://ab-science.excalibra.com/ab-science-announces-masitinib-patent-granted-in-japan-for-the-treatment-of-amyotrophic-lateral-sclerosis-strengthening-the-companys-intellectual-property-position-until-2037/ 2026-08-04T12:30:50+00:00 https://ab-science.excalibra.com/results-of-masitinib-in-als-selected-for-a-scientific-platform-presentation-at-the-aan-2023-including-long-term-survival-analysis-and-a-new-analysis-of-patient-population-with-no-complete-loss-of-fun/ 2026-08-04T12:31:28+00:00 https://ab-science.excalibra.com/ab-science-announces-that-it-has-submitted-its-response-to-the-day-120-questions-in-the-ema-regulatory-review-of-masitinib-in-amyotrophic-lateral-sclerosis-and-clarifies-the-new-timeline-for-respondin/ 2026-08-04T12:36:34+00:00 https://ab-science.excalibra.com/ab-science-webcast-microtubule-destabilizer-agents-mda-platform/ 2026-08-04T12:37:08+00:00 https://ab-science.excalibra.com/ab-science-will-host-a-live-webcast-on-its-microtubule-destabilizer-agents-mda-platform-on-thursday-march-16-2023-from-6pm-to-7pm-cet/ 2026-08-04T12:37:51+00:00 https://ab-science.excalibra.com/ab-science-reports-a-first-complete-bone-marrow-response-in-a-relapsed-refractory-acute-myeloid-leukemia-patient-from-the-very-low-dose-arm-of-its-ab8939-phase-i-ii-clinical-trial-ab18001/ 2026-08-04T12:40:43+00:00 https://ab-science.excalibra.com/publication-of-the-masitinib-pivotal-phase-3-clinical-trial-in-alzheimers-disease-in-the-journal-alzheimers-research-therapy/ 2026-08-04T12:41:53+00:00 https://ab-science.excalibra.com/ab-science-announces-the-drawdown-of-the-second-tranche-of-6-million-euros-under-its-financing-agreement-with-the-european-investment-bank/ 2026-08-04T12:42:32+00:00 https://ab-science.excalibra.com/ab-science-has-received-approval-from-the-u-s-food-and-drug-administration-fda-to-initiate-the-confirmatory-phase-3-study-with-masitinib-in-the-treatment-of-progressive-multiple-sclerosis/ 2026-08-04T12:45:25+00:00 https://ab-science.excalibra.com/masitinib-receives-orphan-drug-status-for-the-treatment-of-amyotrophic-lateral-sclerosis-in-switzerland/ 2026-08-04T12:46:17+00:00 https://ab-science.excalibra.com/ab-science-announces-the-drawdown-of-the-first-tranche-of-6-million-euros-under-its-financing-agreement-with-the-european-investment-bank/ 2026-08-04T12:46:50+00:00 https://ab-science.excalibra.com/ab-science-receives-notice-of-deficiency-nod-from-health-canada-for-masitinib-in-the-treatment-of-amyotrophic-lateral-sclerosis-als/ 2026-08-04T12:47:26+00:00 https://ab-science.excalibra.com/positive-recommendation-of-the-data-and-safety-monitoring-board-to-continue-the-phase-2-study-evaluating-masitinib-in-combination-with-isoquercetin-in-covid-19/ 2026-08-04T12:50:21+00:00 https://ab-science.excalibra.com/communication-from-ab-science-following-the-decision-of-the-enforcement-committee-of-the-french-market-regulator-amf/ 2026-08-04T12:50:46+00:00 https://ab-science.excalibra.com/webcast-presentation-masitinib-filing-in-the-treatment-of-als-in-canada-and-update-on-ab-science-clinical-program-in-all-indications/ 2026-08-04T12:51:17+00:00 https://ab-science.excalibra.com/financing-of-a-8-5-million-dollars-through-the-issuance-of-convertible-bonds-with-attached-warrants/ 2026-08-04T12:51:46+00:00 https://ab-science.excalibra.com/ab-science-will-host-a-live-webcast-on-february-28-2022-to-provide-details-on-the-masitinib-filing-in-the-treatment-als-in-canada-and-to-provide-an-update-on-its-clinical-program-in-all-indications/ 2026-08-04T12:53:14+00:00 https://ab-science.excalibra.com/publication-of-the-masitinib-positive-pivotal-phase-3-trial-in-progressive-forms-of-multiple-sclerosis-in-the-journal-neurology-neuroimmunology-neuroinflammation/ 2026-08-04T12:54:40+00:00 https://ab-science.excalibra.com/abstract-on-the-long-term-survival-of-masitinib-in-als-has-been-selected-for-a-platform-presentation-at-the-annual-meeting-of-the-spanish-society-of-neurology/ 2026-08-04T12:56:06+00:00 https://ab-science.excalibra.com/authorization-to-resume-patient-enrollment-in-the-phase-2-masitinib-study-of-covid-19/ 2026-08-04T12:56:36+00:00 https://ab-science.excalibra.com/new-authorizations-to-resume-patient-enrollment-in-phase-3-studies-of-masitinib/ 2026-08-04T12:58:23+00:00 https://ab-science.excalibra.com/latest-clinical-data-on-long-term-survival-analyses-in-als-will-be-presented-at-the-2021-symposium-on-als-mnd/ 2026-08-04T13:00:29+00:00 https://ab-science.excalibra.com/results-from-masitinib-study-ab12003-in-prostate-cancer-have-been-presented-at-the-2021-american-urological-association/ 2026-08-04T13:01:58+00:00 https://ab-science.excalibra.com/second-authorization-to-resume-patient-enrollment-in-the-phase-3-study-of-masitinib-in-mastocytosis/ 2026-08-04T13:02:46+00:00 https://ab-science.excalibra.com/first-authorization-to-resume-patient-enrollment-in-the-phase-3-study-of-masitinib-in-als/ 2026-08-04T13:03:56+00:00 https://ab-science.excalibra.com/publication-of-a-pathogenic-mechanism-triggered-by-mast-cells-in-the-als-spinal-cord-that-can-be-targeted-by-masitinib/ 2026-08-04T13:04:19+00:00 https://ab-science.excalibra.com/qa-press-release-following-up-on-the-june-28-2021-press-release-relating-to-an-agreement-with-historical-shareholders/ 2026-08-04T13:14:37+00:00 https://ab-science.excalibra.com/results-from-phase-3-ab09004-study-on-alzheimers-disease-have-been-presented-at-the-annual-alzheimers-association-international-conference-aaic/ 2026-08-04T13:15:03+00:00 https://ab-science.excalibra.com/presentation-of-results-from-phase-3-ab09004-study-on-alzheimers-disease-at-the-annual-alzheimers-association-international-conference-aaic/ 2026-08-04T13:16:35+00:00 https://ab-science.excalibra.com/publication-in-the-world-renowned-journal-science-confirms-potential-of-masitinib-as-a-treatment-of-covid-19-with-anti-viral-activity-against-sars-cov-2-and-all-tested-variants-of-concern/ 2026-08-04T13:17:00+00:00 https://ab-science.excalibra.com/publication-of-new-survival-data-showing-that-masitinib-extended-survival-in-als-by-25-months-relative-to-placebo/ 2026-08-04T13:22:15+00:00 https://ab-science.excalibra.com/validation-of-the-risk-management-plan-by-the-french-national-agency-ansm-in-order-to-restart-patient-enro/ 2026-08-04T13:22:53+00:00 https://ab-science.excalibra.com/results-of-the-combined-general-shareholders-meeting-of-june-30-2021/ 2026-08-04T13:23:17+00:00 https://ab-science.excalibra.com/signature-of-an-agreement-with-historical-shareholders-to-implement-a-joint-strategy-to-increase-the-value-of-masitinib/ 2026-08-04T14:09:17+00:00 https://ab-science.excalibra.com/results-from-masitinib-study-ab12005-in-pancreatic-cancer-have-been-presented-at-the-2021-asco-annual-meeting/ 2026-08-04T14:10:37+00:00 https://ab-science.excalibra.com/live-of-the-june-30-2021-combined-shareholders-meeting/ 2026-08-04T15:23:38+00:00 https://ab-science.excalibra.com/live-webcast-on-thursday-june-3-2021-following-the-voluntary-hold-in-the-clinical-studies-of-masitinib/ 2026-08-04T15:24:54+00:00 https://ab-science.excalibra.com/ab-science-announces-a-voluntary-hold-in-the-clinical-studies-of-masitinib/ 2026-08-04T15:27:39+00:00 https://ab-science.excalibra.com/results-from-phase-3-study-evaluating-masitinib-in-prostate-cancer/ 2026-08-04T15:32:25+00:00 https://ab-science.excalibra.com/live-webcast-on-thursday-december-17-2020-on-masitinibs-results-in-alzheimers-disease/ 2026-08-04T15:33:12+00:00 https://ab-science.excalibra.com/positive-confirmatory-phase-2-3-study-ab09004-with-masitinib-in-alzheimers-disease/ 2026-08-04T15:33:34+00:00 https://ab-science.excalibra.com/live-webcast-on-friday-december-11-2020-on-masitinibs-results-in-pancreatic-cancer/ 2026-08-04T15:34:35+00:00 https://ab-science.excalibra.com/positive-confirmatory-phase-3-study-ab12005-with-masitinib-in-first-line-pancreatic-cancer-with-pain/ 2026-08-04T15:39:02+00:00 https://ab-science.excalibra.com/signature-of-a-15-0-million-financing-deal-with-the-european-investment-bank/ 2026-08-04T15:42:38+00:00 https://ab-science.excalibra.com/equity-financing-for-a-maximum-of-4-million-shares-with-alpha-blue-oceans-pact/ 2026-08-04T15:43:44+00:00 https://ab-science.excalibra.com/live-webcast-on-masitinib-in-combination-with-isoquercetine-for-the-treatment-of-covid-19-on-monday-may-11-2020/ 2026-08-04T16:18:36+00:00 https://ab-science.excalibra.com/presentation-of-the-results-from-the-phase-3-ab07015-study-in-severe-asthma-at-the-eaaci-2020-annual-congress/ 2026-08-04T16:19:08+00:00 https://ab-science.excalibra.com/authorization-by-ansm-to-initiate-phase-2-study-evaluating-masitinib-in-combination-with-isoquercetin-for-the-treatment-of-covid-19/ 2026-08-04T16:19:21+00:00 https://ab-science.excalibra.com/annual-financial-results-as-of-31-december-2019/ 2026-08-04T16:19:34+00:00 https://ab-science.excalibra.com/2017/ 2026-08-04T16:19:48+00:00 https://ab-science.excalibra.com/2018/ 2026-08-04T16:20:48+00:00 https://ab-science.excalibra.com/2019/ 2026-08-04T16:21:01+00:00 https://ab-science.excalibra.com/2020/ 2026-08-04T16:21:15+00:00 https://ab-science.excalibra.com/letter-to-our-stakeholders-on-covid-19-pandemic-impact-on-ab-science-studies/ 2026-08-04T16:21:33+00:00 https://ab-science.excalibra.com/fda-clears-masitinib-ind-in-amyotrophic-lateral-sclerosis-allowing-u-s-patient-enrollment-to-commence-in-phase-3-study/ 2026-08-04T16:21:52+00:00 https://ab-science.excalibra.com/summary-of-webcast-with-key-opinion-leaders-on-indolent-systemic-mastocytosis-2/ 2026-08-04T16:22:36+00:00 https://ab-science.excalibra.com/new-fundraising-of-eur-12-3-million/ 2026-08-04T16:22:50+00:00 https://ab-science.excalibra.com/positive-top-line-phase-2b-3-results-for-masitinib-in-progressive-forms-of-ms/ 2026-08-04T16:23:04+00:00 https://ab-science.excalibra.com/fda-green-lights-u-s-patient-enrollment-in-masitinib-phase-3-study-in-metastatic-castrate-resistant-prostate-cancer/ 2026-08-04T16:23:19+00:00 https://ab-science.excalibra.com/publication-of-new-results-in-in-the-peer-reviewed-journal-glia-that-further-support-masitinib-s-potential-mode-of-action-in-als/ 2026-08-04T16:23:33+00:00 https://ab-science.excalibra.com/publication-of-three-ab8939-scientific-abstracts-in-the-special-ash-annual-meeting-issue-of-blood/ 2026-08-04T16:24:12+00:00 https://ab-science.excalibra.com/webcast-on-masitinib-in-severe-asthma-on-december-2-2019/ 2026-08-04T16:24:24+00:00 https://ab-science.excalibra.com/summary-of-webcast-with-key-opinion-leaders-on-indolent-systemic-mastocytosis/ 2026-08-04T16:24:37+00:00 https://ab-science.excalibra.com/clarification-regarding-the-article-in-the-newspaper-les-echos-related-to-the-investigation-by-the-french-market-authorities/ 2026-08-04T16:24:50+00:00 https://ab-science.excalibra.com/ab-science-to-present-results-from-its-ab07002-study/ 2026-08-04T16:24:51+00:00 https://ab-science.excalibra.com/ab-science-corporate-presentation/ 2026-08-04T16:25:06+00:00 https://ab-science.excalibra.com/webconference-presentation-on-masitinib-isoquercetin-in-covid-19/ 2026-08-04T16:25:10+00:00 https://ab-science.excalibra.com/ab8939-receives-orphan-drug-designation-for-acute-myeloid-leukemia-from-fda/ 2026-08-04T16:27:42+00:00 https://ab-science.excalibra.com/first-presentation-of-preclinical-results-for-compound-ab8939-in-the-61st-ash-annual-meeting/ 2026-08-04T16:27:54+00:00 https://ab-science.excalibra.com/financing-agreement-to-pre-finance-the-2019-research-tax-credit/ 2026-08-04T16:28:11+00:00 https://ab-science.excalibra.com/webcast-on-indolent-systemic-mastocytosis-on-november-20-2019/ 2026-08-04T16:28:26+00:00 https://ab-science.excalibra.com/authorization-to-initiate-phase-3-confirmatory-study-in-mastocytosis/ 2026-08-04T16:28:41+00:00 https://ab-science.excalibra.com/update-on-masitinib-programs-timelines/ 2026-08-04T16:32:43+00:00 https://ab-science.excalibra.com/first-half-of-2019-results/ 2026-08-04T16:32:59+00:00 https://ab-science.excalibra.com/10m-raised-through-a-private-placement/ 2026-08-04T16:33:11+00:00 https://ab-science.excalibra.com/ab-science-to-present-at-two-upcoming-conferences-in-september-2019/ 2026-08-04T19:34:57+00:00 https://ab-science.excalibra.com/update-on-masitinib-clinical-program/ 2026-08-04T19:35:13+00:00 https://ab-science.excalibra.com/results-of-masitinib-study-in-metastatic-melanoma/ 2026-08-04T19:35:31+00:00 https://ab-science.excalibra.com/ab-science-corporatate-presentation/ 2026-08-04T19:36:23+00:00 https://ab-science.excalibra.com/summary-of-the-webconference-held-on-july-8-2019/ 2026-08-04T19:36:56+00:00 https://ab-science.excalibra.com/publication-of-the-positive-phase-2-3-clinical-trial-with-masitinib-in-als-in-the-journal-alsfd-2/ 2026-08-04T19:37:23+00:00 https://ab-science.excalibra.com/publication-of-the-positive-phase-2-3-clinical-trial-with-masitinib-in-als-in-the-journal-alsfd/ 2026-08-04T19:38:08+00:00 https://ab-science.excalibra.com/validation-of-the-ab8939-clinical-development-plan-through-regulatory-authority-scientific-advice-procedure/ 2026-08-04T19:38:55+00:00 https://ab-science.excalibra.com/results-of-interim-analysis-for-masitinib-in-alzheimer-s-disease/ 2026-08-04T19:40:18+00:00 https://ab-science.excalibra.com/june-14-2019-web-conference-presentation/ 2026-08-04T19:41:12+00:00 https://ab-science.excalibra.com/positive-idmc-recommendation-following-interim-analysis-in-pancreatic-cancer/ 2026-08-04T19:41:35+00:00 https://ab-science.excalibra.com/upcoming-news-flow/ 2026-08-04T19:42:01+00:00 https://ab-science.excalibra.com/updated-corporate-overview/ 2026-08-04T19:43:11+00:00 https://ab-science.excalibra.com/summary-of-the-webconference-held-on-june-5-2019/ 2026-08-04T19:43:50+00:00 https://ab-science.excalibra.com/june-5-2019-web-conference/ 2026-08-04T19:44:26+00:00 https://ab-science.excalibra.com/summary-of-the-webconference-held-on-june-4-2019/ 2026-08-04T19:45:13+00:00 https://ab-science.excalibra.com/june-4-2019-web-conference-presentation/ 2026-08-04T19:45:45+00:00 https://ab-science.excalibra.com/web-conference-on-june-4-and-5-2019/ 2026-08-04T19:46:39+00:00 https://ab-science.excalibra.com/lifting-of-the-ansm-clinical-hold/ 2026-08-04T19:47:04+00:00 https://ab-science.excalibra.com/annual-financial-results-as-of-31-december-2018/ 2026-08-04T19:49:07+00:00 https://ab-science.excalibra.com/presentation-of-new-masitinib-preclinical-data-in-als-at-the-2019-muscular-dystrophy-association-conference/ 2026-08-04T19:49:33+00:00 https://ab-science.excalibra.com/acceptance-of-abstract-for-oral-presentation-at-the-2019-muscular-dystrophy-association-conference/ 2026-08-04T19:50:09+00:00 https://ab-science.excalibra.com/update-on-the-restructuring-of-the-ab-science-clinical-development-department-in-2018/ 2026-08-04T19:51:18+00:00 https://ab-science.excalibra.com/patients/ 2026-08-04T19:51:39+00:00 https://ab-science.excalibra.com/wp-content/uploads/2018/12/patients.jpg https://ab-science.excalibra.com/ab-science-announces-that-the-masitinib-phase-3-study-in-alzheimer-s-disease-has-completed-patient-recruitment/ 2026-08-04T19:52:01+00:00